Drug, bio-affecting and body treating compositions inventions 11/08

20080292544 - Modified proteins, designer toxins, and methods of making thereof: The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are... Agent: Fulbright & Jaworski, L.L.P.

20080292545 - Functionalized encoded apoferritin nanoparticles and processes for making and using same: Apoferritin nanoparticles with functionalized surfaces have been prepared that include preselected agents within the cavity of the apoferritin molecule and preselected functionalized surface characteristics on the outer surface of the nanoparticle. Such materials provide for utilization and selective modification in a variety of applications including therapeutic and diagnostic uses. Examples... Agent: Battelle Memorial Institute Attn:IPServices, K1-53

20080292546 - Compositions and methods for treating and diagnosing cancer: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.... Agent: Casimir Jones, S.c.

20080292547 - Novel imaging agents for fibrosis: The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. Also provided is a pharmaceutical composition comprising the imaging agent... Agent: Ge Healthcare, Inc.

20080292549 - High affinity melan-a t cell receptors: The present invention provides TCRs having an affinity (KD) of less than or equal to 3 μM, and/or an off-rate (koff) of 1×10−3 S−1 or slower, for the AAGIGILTV-HLA-A*0201 complex. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancer cells presenting that complex.... Agent: Banner & Witcoff, Ltd.

20080292550 - Fluorinated 3'-deoxythymidine derivatives, a method for their preparation and their use: e

20080292551 - Method to produce hyperpolarised carboxylates: The invention relates to a dynamic nuclear polarisation method for producing hyperpolarised carboxylates of organic amines and amino compounds and compositions for use in that method. The DNP agent preferably is a stable oxygen-based, sulphur-based or carbon-based trityl radical. Optionally a paramagnetic metal ion is present.... Agent: Ge Healthcare, Inc.

20080292552 - Pet radiotracers: The invention relates to novel 18F-labelled compounds which may be suitable for use as Positron Emission Tomography (PET) radiotracers, and to processes for preparation of such. The 18F-labelled compounds of the invention comprise a [18F]fluoroalkenyl group.... Agent: Ge Healthcare, Inc.

20080292553 - Phosphoramidate derivatives of fau: The present invention provides phosphoramidate derivatives of a furanosyluracil analog, FAU, that can effectively deliver FAU monophosphate, or a derivative thereof, intracellularly. FAU-Phosphoramidate diesters can bypass the first step of phosphorylation and be activated intracellularly so as to be converted to nucleoside monophosphates. This results in improved formation of nucleoside... Agent: Schwegman, Lundberg & Woessner, P.A.

20080292554 - Cellular labeling for nuclear magnetic resonance techniques: The disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for... Agent: Ropes & Gray LLP

20080292557 - Compounds, compositions and methods for medical imaging of parkinson's disease: Compounds, compositions and methods for the detection and diagnosis of Parkinson's disease. Derivative lycerophosphocholine (GPC) compounds are used as a detection and diagnostic aid to measure progression of Parkinson's disease by detecting GPC binding to α-synuclein. Derivative CPG compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These... Agent: Lesavich High-tech Law Group, P.C.

20080292555 - Quantitative two-photon flow cytometry: A method and apparatus of multi-dye analysis of particles using flow cytometer. The method includes dying particles to be detected using two or more dyes; urging the particles through a capillary in a non-uniform flow; exciting a first of the particles within the capillary using a multiphoton excitation laser beam... Agent: Harness, Dickey & Pierce, P.L.C

20080292556 - Target vector with activable imaging function: The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment, said constructs being further bound to a vector which enables certain cells to be targeted, and said cells to be internalized. The... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080292558 - Colored esmolol concentrate: A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation. In one embodiment, the concentrated esmolol formulation allows identification of the concentrate even after transfer of the concentrate out of a labeled primary container. The concentrated esmolol formulation can include from about... Agent: Baxter Healthcare Corporation

20080292559 - Method of treating tuberculosis with interferons: A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.... Agent: Klauber & Jackson

20080292561 - Pyrazolo-pyrimidine derivatives as anti-inflammatory agents: m

20080292560 - Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent: A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixtures thereof; 0% to about 48% of at least one secondary solvent;... Agent: Wilmerhale/boston

20080292563 - Inhalable powder containing tiotropium: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080292562 - Medicaments for inhalation comprising pde iv inhibitors and enantiomerically pure glycopyrrolate salts: The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors (2) and salts of formula (1) wherein X may have the meanings defined in the description and claims, and their use in the treatment of respiratory complaints.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080292564 - Aerosol compositions containing fluorine substituted olefins and methods and systems using same: Various compositons, including particularly aerosol compositions, containing fluorinated olefins, including particularly tetra- and penta-fluorpropenes, in a variety of applications are disclosed.... Agent: Honeywell International Inc.

20080292566 - Oral composition containing morin: The present invention relates to an oral composition useful to reduce inflammatory processes. More specifically, the invention relates to a composition consisting essentially of an anti-oxidative effective amount of morin and a water-humectant phase, and to a composition comprising an anti-oxidative effective amount of morin, one or more anti-bacterial agents... Agent: Colgate-palmolive Company

20080292565 - Tooth fluoridating and remineralizing compositions and methods, based on nanoaggregate formation: Compositions and methods for forming, in an aqueous environment, a nanoaggregate of calcium fluoride and amorphous calcium phosphate-containing compound, such as amorphous calcium phosphate fluoride or amorphous calcium carbonate phosphate fluoride are described. The nanoaggregate (or nanocomposite) can release calcium, phosphate, and fluoride, and ultimately convert to the tooth mineral,... Agent: Banner & Witcoff, Ltd.

20080292568 - 3-deoxyglucosone and skin: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080292569 - Method for improving efficacy of surfactants prevention of lamellar mesophases temperature stabilization of the single phase region and a method for reducing boundary surface tension in micro-emulsions containing silicone oils by means of additives and su: Disclosed is a method for improving efficacy of surfactants, prevention of lamellar mesophases, temperature stabilization of the single phase region and a method for reducing boundary surface tension in micro-emulsions containing silicone oils by means of additives and a surfactant/oil mixture. The above effects are achieved, whereby an additive of... Agent: Jordan And Hamburg LLP

20080292567 - Uv-protective cosmetic preparation and use of decorative pigments comprising a protective layer: The invention relates to a UV-protective cosmetic preparation comprising one or more UV absorbers, which cosmetic preparation comprises effect pigments provided with at least one protective coating. The invention also relates to the use of effect pigments having at least one protective coating for the production of a UV protective... Agent: Ostrolenk Faber Gerb & Soffen

20080292570 - Polymer-based pigment-bearing ink: A cosmetic water-based ink containing at least one acryl-based polymer, at least one polymeric ionic thickener, at least one anionic or amphoteric-ionic surfactant, at least one material in particle form and at least one non-ionic surfactant, wherein the non-ionic surfactant is a compound which contains between 4 and 8 units... Agent: Bachman & Lapointe, P.C.

20080292571 - Deodorant composition with monocyclic, unsaturated sequiterpene alcohols and glyceryl monoalkyl ethers as synergistic active deodorant agents: A clear deodorant stick composition consisting essentially of from 45 to about 75% of glycerin as solvent for soap gelling agent; and from 0.5 to about 2% alkali metal bicarbonate and from 0.5 to about 2.5% nonionic surfactants as clarity enhancer; and from 0.1 to about 0.5% natural alpha Bisabolol... Agent: The Halvorson Law Firm

20080292572 - Production of structured hairstyles using a composition comprising reactive silicone compounds: The present invention relates to the treatment of human keratin fibres to obtain structured hairstyles, for example with structured locks, which consists in applying a composition comprising at least one compound X and Y, at least one of which is a silicone compound, these compounds furthermore being capable of reacting... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080292574 - Hair conditioning composition comprising polyalkylsiloxane mixture, aminosilicone, and silicone copolymer emulsion: Disclosed is a hair conditioning composition comprising: a polyalkylsiloxane mixture of a first polyalkylsiloxane which is non-volatile and has a higher viscosity and a second polyalkylsiloxane which is non-volatile and has a higher viscosity; an aminosilicone; and a silicone copolymer emulsion. The composition of the present invention provide clean feel... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080292575 - Hair conditioning composition comprising quaternized silicone polymer, grafted silicone copolyol, and dialkyl cationic surfactant: Disclosed is a hair conditioning composition comprising: (a) a quaternized silicone polymer; (b) a grafted silicone copolyol; (c) a cationic surfactant system comprising a dialkyl quaternized ammonium salt cationic surfactant; (d) a high melting point fatty compound; and (e) an aqueous carrier. The present invention can provide improved conditioning benefits... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080292573 - Method for treating hair with a reactive vinyl silicone capable of reacting via hydrosilylation: s

20080292576 - Method for identifying hair conditioner-resistant hair-binding peptides and hair benefit agents therefrom: A method for identifying hair conditioner-resistant hair-binding peptides is described. The hair conditioner-resistant hair-binding peptides bind strongly to hair from a hair conditioner matrix and are stable therein. Peptide-based benefit agents, such as hair conditioners and hair colorants, based on the hair conditioner-resistant hair binding peptides are described. The peptide-based... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080292577 - Novel ethylene copolymers, compositions comprising same and preparation and treatment methods: The invention concerns novel ethylene copolymers comprising polyethylene glycol (meth)acrylate monomers, cationic monomers, and optionally amphoteric, anionic and/or hydrophilic nonionic monomers, neutralized by particular neutralizing agents. The invention also concerns composition in particular cosmetic or pharmaceutical comprising said copolymers, as well as methods for preparing said copolymers, and cosmetic treatment... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080292578 - Sustained release air freshening device: This invention relates to a device that provides controlled release of a fragrant or deodorizing substance: the fragrant or deodorizing substance being solublized with an appropriate carrier solvent within a polymeric matrix. The layers function as protective barriers, semi-permeable membranes, fragrance reservoirs, and adhesives. The device is capable of delivering... Agent: Wood, Herron & Evans, LLP

20080292579 - Polymer-based serum albumin substitute: This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers.... Agent: Bozicevic, Field & Francis LLP

20080292580 - Treatment of inflammatory diseases: An aqueous solution or at least one polyether polyol in a fluid for administration to a mammal, such as a human being, wherein the at least one polyether polyol has a molecular weight of from 200 to 4000 and is dissolved in the aqueous fluid in a concentration of from... Agent: Speckman Law Group PLLC

20080292581 - Interleukin-11 fusion proteins: The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or antiinflammatory properties, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of... Agent: Fox Rothschild LLP

20080292583 - Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione following autologous stem cell transplantation: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080292582 - Novel inhibitors of glutaminyl cyclase: t

20080292584 - Metaxalone products, method of manufacture, and method of use: Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or... Agent: Cantor Colburn, LLP

20080292585 - Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom: Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of Cancer.... Agent: Clark & Elbing LLP

20080292588 - 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives: The invention is directed to 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080292586 - Method and use of interferon compositions for the treatment of avian influenza: The present invention provides methods and uses for an interferon composition in the treatment of avian influenza. Transmission of avian influenza virus H5N1 to humans has been shown to be highly pathogenic. The present invention provides for methods of treatment that provide a broad spectrum, first line defense against avian... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080292589 - Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080292587 - Oximyl dipeptide hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080292590 - Soluble receptors and methods for treating autoimmune or demyelinating diseases: The present invention relates to novel therapeutic protein useful in the treatment of diseases, in particular in human subjects. The results of the inventor strongly support the use of soluble IL-18Rα in the treatment of diseases such as autoimmune or demyelinating disease, in particular Multiple Sclerosis (MS). Accordingly, the invention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080292591 - Tumor mouse models using lentiviral vectors: This invention provides model systems for study of tumors. Model cells and model animals are prepared to mimic characteristics of natural clinical tumors. The tumor models can be contacted with putative modulators to screen for therapeutics and to help understand tumorigenic processes. Model animals can include model cells, closely correlated... Agent: Quine Intellectual Property Law Group, P.C.

20080292595 - Aav vectors for gene delivery to the lung: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.... Agent: Robins & Pasternak

20080292593 - Gene therapy for spinal cord disorders: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an... Agent: Genzyme Corporation Legal Department

20080292594 - Mutant reoviruses and methods of making and using: Provided herein is a mutant reovirus (e.g., a genetically-engineered ISVP). Compositions including mutant reoviruses and methods of using such mutant reoviruses are also provided.... Agent: Fish & Richardson P.C.

20080292592 - Oncolytic adenovirus armed with therapeutic genes: The present invention involves compositions and methods for treating preventing cancer using compositions including replication competent adenovirus. The application competent adenovirus may or may not encode a therapeutic polynucleotide.... Agent: Fulbright & Jaworski L.L.P.

20080292602 - T cell receptors which specifically bind to vygfvracl-hla-a24: The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting the complex.... Agent: Banner & Witcoff, Ltd.

20080292603 - Treatment and prevention of neurodegenerative diseases using gene therapy: Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in... Agent: Foley & Lardner LLP

20080292604 - Canine probiotic lactobacilli: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080292596 - Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates: Methods are described for producing reduced, methylated, biologically active forms of folate, including 5-methyltetrahydrofolate (i.e. 5-methyltetrahydropteroylglutamic acid), 5-formyltetrahydrofolate, 10-formyltetrahydrofolate and tetrahydrofolate. Edible mushroom-producing fungi are cultivated to enhance the uptake of pteroylmonoglutamate (synthetic folate) into edible portions of the plants. The mushroom-producing fungi reduce and methylate the pteroylmonoglutamates into activated... Agent: Mccarter & English LLP Cityplace I

20080292598 - Chimeric transplant: Compositions comprising amniotic fluid stem cells which are derived from non-identical donor sources. Donors may be non-identical siblings, non-identical twins, and/or donors which are unrelated by a familial relationship. Also disclosed are methods for making such amniotic stem cell compositions, and methods for their use, such as therapeutic stem cell... Agent: Stemedica Cell Technologies, Inc

20080292599 - Chondrogenic compositions and methods of use: The invention provides a method of treatment joint and disk disease comprising administering to the subject in need thereof a novel composition comprising a substantially purified plurality of cells enhanced with at least one bioactive factor capable of causing at least a portion of the plurality of cells to express... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20080292600 - Treatment of graft-versus-host disease: This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.... Agent: Jhk Law

20080292601 - Treatment of graft-versus-host disease with il-10 expressing cells: This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.... Agent: Jhk Law

20080292597 - Umbilical cord stem cell composition & method of treating neurological diseases: A neurological disease is treated by administering to a patient a therapeutically effective amount of a composition including human umbilical cord stem cells. The composition may include growth factors mixed with the stem cells immediately prior to being administered. A specific pre and post transplantation protocol provides optimal methods for... Agent: Connors Associates

20080292605 - Materials for stimulation of hematopoiesis by ex vivo activated cells: A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from a plastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is... Agent: Dardi & Associates, PLLC US Bank Plaza

20080292607 - Nutraceutical agent for attenuating the neurodegenerative process associated with parkinson's disease: This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate and/or oxaloacetate, fruit extracts and anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant... Agent: Elizabeth Mazzio Florida A & M University

20080292606 - Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability: Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamin B6 and mixtures thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080292608 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.... Agent: Genomics Institute Of The Novartis Research Foundation

20080292609 - Use of arginase in combination with 5fu and other compounds for treatment of human malignancies: The present invention provides a method for treating cancer in a human patient by reducing the physiological arginine levels to below 10 μM in combination with administering an anti-neoplastic compound. The present invention also provides a pharmaceutical composition comprising an arginine reducing compound, such as pegylated human arginase I, and... Agent: EagleIPLimited

20080292612 - Composition containing several botulic toxins: The invention concerns a composition including at least one botulinum neurotoxin type A1, and one botulinum neurotoxin type A the amino acid sequence of which as at least 5% difference with the amino acid sequence of botulinum neurotoxin type A1.... Agent: Hunton & Williams LLP Intellectual Property Department

20080292610 - Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders: A medicament containing enzymes from ciliates selected from the group consisting of hydrolases, lipases, proteases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases.... Agent: Jacobson Holman PLLC

20080292611 - Novel methods of treatment and delivery modes: The invention relates to a novel method of administration, and device employed in the method, for administering a treatment species to the lungs of a recipient patient. The method involves introducing the device of the invention to the venous system of the patient, the size of the treatment species being... Agent: Haynes And Boone, LLP

20080292613 - Food supplement based on group b vitamins, trace elements and -3 and/or 6- fatty acids and use of this food supplement in the simultaneous treatment of localized cellulite and slackening of the skin: The present invention relates to the use of a combination of group B vitamins, trace element(s), at least one oil comprising essential Ω-3 and/or Ω-6 fatty acids and an excipient suitable for oral administration, for use in the simultaneous treatment of excess weight and slackening of the skin localized in... Agent: Foley And Lardner LLP Suite 500

20080292548 - Compounds and methods for 18f labeled agents: The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in... Agent: Millen, White, Zelano & Branigan, P.C.

20080292617 - Antibody against a peptide derived from human mutant lamin a protein and uses thereof: Nearly all subjects affected with Hutchinson Gilford progeria syndrome (HGPS) carry mutation LMNA G608G (GGC>GGT), within exon 11 of LMNA activating a splicing donor site which leads to a deletion of 50 amino acids at the carboxyl-terminal of prelamin A. The invention provides an isolated peptide of sequence GAQSPQNC. The... Agent: Wilmerhale/columbia University

20080292615 - Diagnosis and treatment of disease: We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual. Methods of making medicaments... Agent: Workman Nydegger

20080292614 - Dna sequences for human angiogenesis genes: Novel nucleic acid sequences and encoded polypeptides involved in the process of angiogenesis are provided. In particular, provided are a BNO69 nucleic acid of SEQ ID NO: 1 and a BNO69 polypeptide of SEQ ID NO: 115. Methods are provided for treating subjects having pathologies associated with angiogenesis and for... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080292618 - Intranuclear protein transduction through a nucleoside salvage pathway: Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to... Agent: Dla Piper US LLP

20080292616 - Topical formulations of histone deacetylase inhibitors and methods using the same: Disclosed are topical compositions comprising at least one histone deacetylase (HDAC) inhibitor (HDI) and a carrier comprising petrolatum. Methods for using such compositions to treat or inhibit cancer and various skin diseases are also disclosed.... Agent: Leydig, Voit & Mayer, Ltd.

20080292626 - Kinesin inhibitors: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080292623 - Mammalian cell membrane proteins; related reagents: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.... Agent: Dnax Research Inc. Legal Department

20080292624 - Method of detecting and treating tuberous sclerosis complex associated disorders: Disclosed are methods of detecting and treating tuberous sclerosis complex associated disorders. Also disclosed are methods of identifying agents for treating tuberous sclerosis complex associated disorders.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn,

20080292622 - Methods of evaluating patients: Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080292621 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20080292625 - Prevention and treatment of cerebral amyloid angiopathy: The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody... Agent: Townsend And Townsend And Crew, LLP

20080292620 - Prlr-specific antibody and uses thereof: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.... Agent: Novartis Vaccines And Diagnostic, Inc.

20080292619 - Pharmaceutical composition containing meltrin antagonist: Mainly concerning the pharmaceutical field, it is intended to exert an inhibitory effect on the function of meltrin α of promoting the differentiation of adipocytes by preparing a compound serving as an antagonist to meltrin α (for example, an antisense inhibiting the expression of a meltrin α gene or an... Agent: Birch Stewart Kolasch & Birch

20080292627 - Compositions and methods for treating mood and anxiety disorders: The invention relates method of disrupting the interface between Gsα and tubulin. The disruption of this interaction is a mechanism for treatment of mood and anxiety disorders and this interaction may be used to screen for and design therapeutics for mood and anxiety disorders.... Agent: Marshall, Gerstein & Borun LLP

20080292629 - System clock generation circuit: A system clock signal generator circuit comprising a first PLL circuit that is frequency and phase locked to a wobble signal; a frequency and phase comparator for comprising a first output signal from the first PLL circuit with a system clock signal as frequency divided by M and for outputting... Agent: Cheryl Liljestrand Tanox

20080292630 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20080292631 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20080292628 - Chimeric protein: A fusion protein containing a first segment that is located at the amino terminus of the fusion protein and specifically binds to and neutralizes a first cytokine or growth factor; and a second segment that is located at the carboxyl terminus of the fusion protein and specifically binds to a... Agent: Occhiuti Rohlicek & Tsao, LLP

20080292635 - Allergenic latex protein: The present invention relates to a protein found in natural rubber that can induce an allergic reaction in persons who have been sensitised to it. The invention provides for the process of isolating and purifying the protein and describes the characteristics of the protein, including its molecular weight, isoelectric point,... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080292636 - Chemokine panec-2 polynuleotides, polypeptides, antibodies and methods of making and using them: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2,... Agent: Foley And Lardner LLP Suite 500

20080292633 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080292634 - Nontypable haemophilus infuenzae virulence factors: The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes and the polypeptides encoded by these polynucleotide sequences. The invention also relates to a novel 110 kDa NTHi... Agent: Marshall, Gerstein & Borun LLP

20080292632 - Irta2 antibodies and methods of use: Antibodies that specifically bind the extracellular domain of IRTA2 are disclosed herein. In one embodiment, these antibodies do not specifically bind IRTA1, IRTA3, IRTA4, or IRTA5. In one example, the antibodies are humanized antibodies. The antibodies can be conjugated to effector molecules, including detectable labels, radionucleotides, toxins and chemotherapeutic agents.... Agent: Klarquist Sparkman, LLP

20080292638 - Tgf-beta binding antibodies: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.... Agent: Eli Lilly & Company

20080292637 - Therapeutic uses of a3 adenosine receptor antibodies: The present invention concerns the use of an anti-A3 adenosine receptor (A3AR) immunoglobulin-based molecule for the preparation of a pharmaceutical composition for the treatment of a pathological condition associated with a high level of expression of A3 adenosine receptor. Further provided by the invention is a method of treating a... Agent: Nath & Associates

20080292639 - Humanized anti-amyloid antibody: Compositions for treating neurodegenerative or amyloidgenic disorders such as Alzheimer's disease (AD) are provided. More particularly, humanized anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.... Agent: Marshall, Gerstein & Borun LLP

20080292640 - Methods for the treatment of il-1beta related diseases: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.... Agent: Bell, Boyd, & Lloyd LLC

20080292641 - Antigenic gm-csf peptides and antibodies to gm-csf: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the... Agent: Woodcock Washburn LLP

20080292642 - Crystalline anti-human il-12 antibodies: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.... Agent: Abbott Bioresearch

20080292643 - Leukocyte inactivation module: The present invention provides a module for reducing the activity of leukocytes which comprises a carrier and a ligand that is linked to the carrier and is suitable for interacting with a leukocyte receptor. Furthermore, the present invention provides a process for reducing the activity of leukocytes using said module.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080292644 - Compositions and methods for identifying response targets and treating flavivirus infection responses: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the... Agent: Greenberg Traurig LLP (la)

20080292645 - Antibody or antibody fragment coupled with an immunogenic agent: An immunogenic conjugate includes a target cell-specific circulating molecule and at least one immunogenic agent, the immunogenic agent being coupled by any appropriate means with the circulating molecule. Also described is a method for preparing the immunogenic conjugate and its use for treating cancers or autoimmune diseases.... Agent: Young & Thompson

20080292646 - Recombinant fusion protein and polynucleotide construct for immunotoxin production: The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of... Agent: Winston & Strawn LLP Patent Department

20080292649 - Composition for improving membrane composition and functioning of cells: c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system,... Agent: Banner & Witcoff, Ltd.

20080292647 - Melanoma antigens and their use in diagnostic and therapeutic methods: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention... Agent: Leydig, Voit & Mayer, Ltd.

20080292648 - Synthetic agonists of tlr9: The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.... Agent: Keown & Zucchero, LLP

20080292650 - Therapeutic and diagnostic peptides: This invention generally relates to peptides useful for medical diagnosis and treatment of pathogenic disorders. More specifically, the invention relates to immunostimulatory peptides which can stimulate the production of therapeutically beneficial cytokines and, in combination with antibodies against human pathogens such as the immunodeficiency virus (HIV), inhibit replication of such... Agent: Schmeiser Olsen & Watts

20080292651 - Skin firming and lifting compositions and methods of use: Disclosed is a composition comprising a combination of: Polygonum fagopyrum seed extract, Chlorella vulgaris extract, palmitoyl wheat protein hydrolysate, algae extract, and tripeptide. The composition may further comprise one or more of the following: Citrus unshiu peel extract, Sphacelaria scoparia extract, Bambusa vulgaris extract, Pisum sativum (pea) extract, Evodia rutaecarpa... Agent: In Re: 28533 Brinks, Hofer, Gilson & Lione

20080292655 - Enhancement of the immune response for vaccine and gene therapy applications: Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in... Agent: Novartis Vaccines And Diagnostics Inc.

20080292654 - Human bocavirus and methods of diagnosis and treatment: Human parvovirus, genus Bocavirus, associated with respiratory tract infections in children. Nucleic acid and polypeptide sequences of the virus. Methods and products for diagnosing presence of bocavirus in a sample using nucleic acid probes or primers, or specific binding members such as antibodies. Methods and products for diagnosing past or... Agent: Dann, Dorfman, Herrell & Skillman

20080292653 - Live attenuated antigenically marked classical swine fever virus: Classical swine fever virus is a world-wide distributed highly-contagious disease affecting swine. The two main strategies for diseases control are prophylactic vaccination and non-vaccination stamping out policies. Marker vaccines are a promising strategy. Here we report the rational development of a doubly antigenic marker CSFV experimental live attenuated candidate strain... Agent: Usda, Ars, Ott

20080292652 - Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide: The present invention is in the fields of medicine, immunology, virology and molecular biology. The present invention provides a composition comprising a modified virus-like (VLP) particle derived from RNA bacteriophage AP205. The invention also provides a process for producing the aforementioned VLP. The modified VLP disclosed in the present invention... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080292656 - Combination of a bacterial cell and a biologically active agent: The present invention is related to a combination comprising a first constituent and a second constituent, wherein the first constituent is a bacterial cell which comprises at least one recombinant nucleic acid molecule encoding a phagolysosomal escape peptide or polypeptide; and wherein the second constituent is a biologically active agent.... Agent: Faegre & Benson LLP Patent Docketing

20080292657 - Primate t-lymphotropic viruses: Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population... Agent: Klarquist Sparkman, LLP

20080292658 - Defective influenza virus particles: The invention relates to the field of influenza virus and the vaccination against flu. The invention provides a conditionally defective influenza virus particle having seven different influenza nucleic acid segments. The invention also provides a conditionally defective influenza virus particle lacking an influenza nucleic acid segment selected from the group... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080292659 - Prime boost vaccine for the protection of equines against equine influenza: The present invention therefore provides a method for vaccination of animals against equine influenza, wherein an animal is first vaccinated with a (prime) vaccine comprising an attenuated equine influenza virus, followed by a vaccination with a (boost) vaccine comprising an inactivated equine influenza virus, and wherein the boost vaccine is... Agent: Intervet/schering-plough Animal Health Patent Department

20080292660 - Hexavalent bovine rotavirus reassortant composition designed for use in developing countries: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest... Agent: Townsend And Townsend And Crew, LLP

20080292661 - Use of botulinum toxin for the preparation of a medicament for the treatment of lithiasis of salivary gland, gall bladder, kidney, or pancreas: The invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat a gland, organ or duct obstructed by a naturally formed stone. This method can be applied notably for salivary gland, gall bladder, kidney or pancreas stones.... Agent: Jacobson Holman PLLC

20080292662 - Vaccine comprising recombinant clpp protein of streptococcus pneumoniae: This invention is about vaccine comprising recombinant CLPP protein of Streptococcus pneumoniae. In this study, it was demonstrated that the CLPP was translocated into the cell wall after heat shock. And the immunization of mice with the pneumococcal CLPP prior to challenge with virulent D39 elicited protective immunity against systemic... Agent: Thomas W Adams Renner Otto Boisselle & Sklar

20080292663 - Adjuvant compositions and methods for delivering vaccines: An adjuvant composition is provided that is comprised of a calcium compound, lecithin, and an acrylic polymer. Pharmaceutical compositions are provided which include an antigen and the adjuvant. Methods are provided for stimulating an immune response in a human or animal subject by administering a composition comprising an antigen and... Agent: Stites & Harbison PLLC

20080292664 - Hydrogels and hyaluronic acid and alpha, beta-polyaspartyl-hydrazide and their biomedical and pharmaceutical uses: Compositions and products based on the chemical crosslinking of hyaluronic acid with a polyfunctional polymer having a protein-like structure, bearing hydrazido pendent groups along the polymeric chain. The polymer is preferably, alpha-beta-polyaspartylhydrazide, a biocompatible macromolecule. The materials obtained after crosslinking, specifically hydrogels, undergo a reduced chemical and enzymatic degradation, unlike... Agent: Arent Fox LLP

20080292667 - Nonwoven nanofibrous membranes of silk fibroin for guided bone tissue regeneration and their preparation method: A membrane for guided bone tissue regeneration according to the present invention has a predetermined strength, biocompatibility, and biodegradability, and may maintain a sustained drug release system, when drugs are added in the manufacturing process. Additionally, a membrane for guided bone tissue regeneration according to the present invention may be... Agent: Bachman & Lapointe, P.C.

20080292666 - Preparation for preventing or treating calcium deficiency conditions in mammals: An essentially dry powdered preparation containing a calcium source for the prevention and treatment of calcium deficiency conditions in mammals, e.g. dairy cows, is enclosed in a substantially water soluble, dispersible or disintegrable casing mainly composed of a cellulose material such as e.g. paperboard, cardboard, millboard, or pasteboard, or a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080292665 - Simple mechanical procedure and product for deterring substance abuse: Simple mechanical methods improve safety of a substance that is at risk for abuse. The substance is made in a specified form that tends to deter conversion to powder: and in this form commercially distributed, e.g. wholesale or retail. Preferably that form is enclosed in a harmless container. Preferably the... Agent: Peter I. Lippman

20080292669 - Foamed substrate and method for making same: The present invention provides a foamed and/or aerated substrate for transmucosal and/or transdermal applications. The foamed and/or aerated substrate may be in the form of a film, sheet, strip or wafer. The foamed and/or aerated substrate is suitable for use in applications such as, for example, adhesive denture liners, tooth... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080292668 - Water-free cosmetic preparation: A water-free composition, in particular a cosmetic composition, in the form of a pencil with a cast or extruded lead or a workable paste which is suitable for cosmetic uses, in particular in the field of decorative cosmetics, for coloring, improving the appearance of and caring for keratinic materials such... Agent: Bachman & Lapointe, P.C.

20080292670 - Adhesive and plaster: An adhesive comprising a base with tackiness, an oil and ketoprofen, wherein the adhesive contains no L-menthol, the base is composed at least of a tacky composition comprising an elastomer and a tackifier and/or a tacky polymer containing an unsaturated monomer with a total of 5 or more carbon atoms... Agent: Nath & Associates

20080292671 - Antimicrobial medicotechnical product, process for its preparation and use: The invention relates to a medicotechnical product having an antimicrobial finish of a complex material of metal nanoparticles and macromolecules, the macromolecules being formed at least partially from a polyamino acid.... Agent: Nath & Associates

20080292672 - Active compound-containing solid moulded bodies for external use against parasites on animals: The present invention relates to active compound-containing moulded bodies for external use against parasites on animals.... Agent: Bayer Healthcare LLC

20080292674 - Bioactive agrichemical compositions and use thereof: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.... Agent: Edward K. Welch Ii Ip&l Solution

20080292673 - Bioactive agrichemical compositions and use therreof: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.... Agent: Edward K. Welch Ii Ip&l Solution

20080292675 - Antimicrobial medicotechnical product, process for its production and use: The invention relates to a medicotechnical product having an antimicrobial finish consisting of a complex material of metal nanoparticles and macromolecules, the macromolecules being at least partially formed from amphiphilically modified polyamino acids which contain amino acid units, which aside from the functional groups bonded in the peptide bond contain... Agent: Nath & Associates

20080292676 - Bioactive acid agrichemical compositions and use thereof: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising metal-acid solutions.... Agent: Edward K. Welch Ii Ip&l Solution

20080292677 - Engineered lung tissue, hydrogel/somatic lung progenitor cell constructs to support tissue growth, and method for making and using same: Somatic lung progenitor cell/polymer constructs are disclosed along with methods for isolating somatic lung progenitor cells from adult mammals, seeding the cells onto or into polymeric scaffolds and allowing the cells to differentiate and proliferate into functional lung tissue/polymer implants. A method for treating lung disease, disorders or injuries is... Agent: Robert W Strozier, P.l.l.c

20080292678 - Medical articles having enzymatic surfaces for localized therapy: An enzymatically active medical article is provided, which comprises a medical article and an enzyme disposed at or near a surface of the medical article such that the medical article is provided with an enzymatically active surface. The enzyme is selected, for example, from the group consisting of protease enzymes,... Agent: Mayer & Williams PC

20080292679 - Biodegradable drug delivery system: A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50... Agent: Allergan, Inc.

20080292680 - Hypercompressed polymer particles for controlled release ophthalmic medications: An ophthalmic dispensing device having a polymer which is combined with an ophthalmic therapeutic agent in the form of a microparticle which is hypercompressed to form a controlled release dispensing device for ophthalmic use.... Agent: Hedman & Costigan P.C.

20080292681 - Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic... Agent: Woodcock Washburn LLP

20080292683 - Film shreds and delivery system incorporating same: Compositions are provided that include water soluble or water dispersible film shreds, a carrier and an active, such as, but not limited to a drug, flavoring agent or coloring agent. Also provided are methods of use of the film shreds, such as in improving the dissolution, stability, aesthetics, or taste... Agent: Hoffmann & Baron, LLP

20080292682 - Method for treating allergic dermatitis: A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the... Agent: Haynes And Boone, LLP

20080292684 - Device for delivery of active principles: A device for the delivery of active principles for dermal and, in particular, transdermal application having the form of a two-layered patch consisting of a first layer having a homogeneous composition and comprising at least one active principle, a water-soluble film-forming agent and a hydrophilic adhesive polymer, and of a... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080292685 - Transdermal patch containing isosorbide dinitrate and bisoprolol: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a... Agent: Scully, Scott, Murphy & Presser, P.C.

20080292688 - Liposome and preparation method of the same: The present invention relates to a composition and a method for preparing a liposome, the liposome including a lipid bilayer and an aqueous core contains a hydrophobic or a hydrophilic drug and a component—Vitamin E derivative (d-α tocopheryl polyethylene glycol 1000 succinate; TPGS). TPGS is able to increase the encapsulation... Agent: Bacon & Thomas, PLLC

20080292689 - Method for inhibiting free radicals: A method for inhibiting free radical is provided. The method includes administering to a subject an effective amount of an herbal composition including Polygonum cuspidatum and/or Viola yedoensis. The herbal composition is suitable for mammalian subjects. The Polygonum cuspidatum is selected from fresh Polygonum cuspidatum herbage, and the Viola yedoensis... Agent: Birch Stewart Kolasch & Birch

20080292687 - Methods of treating cancer and other conditions or disease states using lfmau and ldt: The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether... Agent: Coleman Sudol Sapone, P.C.

20080292686 - Vaccine: The present invention provides novel intradermal vaccines and novel uses for adjuvants in the preparation of intradermal vaccines, and also novel methods of treatment comprising them. The intradermal adjuvants, and methods, of the present invention comprise a saponin and a sterol, wherein the saponin and sterol are formulated in a... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080292691 - Bariatric magnetic apparatus and method of manufacturing thereof: A bariatric procedure or delivery apparatus is configured in such a way to deter premature passing of magnetic members through the pylorus. In other exemplary embodiments, the magnetic apparatus includes a plurality of magnetic members, having one of a variety of configurations, wherein plural magnetic poles are disposed on a... Agent: Cantor Colburn, LLP

20080292690 - Multi-membrane immunoisolation system for cellular transplant: This invention relates to an immunoisolation encapsulation system that protects cellular transplants and thus allows cell function and survival without the need of immunosuppression. The immunoisolation system is a multi-component, multi-membrane capsule that allows optimization of multiple design parameters independently for reproducible functions in large animals models.... Agent: Edell, Shapiro & Finnan, LLC

20080292692 - Impermeable capsules: A capsule comprising a core and a shell surrounding and enclosing the core, the shell comprising at least one first polymer having a first water solubility parameter, and at least one second polymer having a water solubility parameter higher than the first water solubility parameter, wherein the second polymer is... Agent: Colgate-palmolive Company

20080292693 - Composition and method for treating digestive system disorders: The present disclosure provides for a novel composition, with active ingredients comprising d-Limonene and Aloe mucilaginous polysaccharides (AMPs), for the treatment of a wide variety of digestive system disorders and diseases, including conditions which affect the stomach, esophagus, bowel, colon, liver or pancreas are considered digestive system diseases and disorders,... Agent: Jennings, Strouss & Salmon, P.L.C

20080292694 - Opioid agonist/antagonist combinations: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective... Agent: Davidson, Davidson & Kappel, LLC

20080292695 - Carvedilol forms, compositions, and methods of preparation thereof: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.... Agent: Cantor Colburn, LLP

20080292696 - enteric sustained-release tablet comprising paroxetine: The present invention relates to an enteric, sustained-release tablet comprising paroxetine or a hydrates or anhydrides of a pharmaceutically acceptable salt thereof as active substance, more particularly to a tablet prepared by coating a sustained-release tablet core containing paroxetine with an enteric polymer, wherein the interaction between the tablet core... Agent: Squire, Sanders & Dempsey L.l.p

20080292697 - Direct compression polymer tablet core: The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method... Agent: Genzyme Corporation Legal Department

20080292698 - Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use: e

20080292700 - Controlled release formulations using intelligent polymers: A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080292699 - Solid pharmaceutical dosage unit for alleviating symptoms of rhinorrhea: A solid pharmaceutical dosage unit for alleviating the symptoms of rhinorrhea. The dosage unit comprises an anticholinergic agent and an antihistamine and, optionally, a decongestant and, when placed in a basket in 500 ml of 0.01 N HCl of 37° C. which is stirred at 100 rpm, releases at least... Agent: Greenblum & Bernstein, P.L.C

20080292701 - Orally disintegrable tablets: An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080292702 - Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same: A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising... Agent: Sughrue Mion, PLLC

20080292703 - Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation, and their use in the pharmaceutical field: The present invention describes a new group of bioconjugates which can be obtained by means of indirect synthesis, via a molecular spacer, between hyaluronic acid and/or its derivatives and drugs with an antitumoral activity belonging to different groups, their preparation process and use in the oncological field. The new derivatives,... Agent: Hedman & Costigan P.C.

20080292705 - Emulsifier system: The invention relates to an emulsifier system, which comprises a nanoparticle with a positive or negative net charge and a hydrophobic compound of opposite charge to the nanoparticle that will bind to the nanoparticle making it hydrophobic and the use of that system for preparing water-in-oil (WIO) emulsions as well... Agent: Unilever Patent Group

20080292704 - Methods and compositions involving polymeric immunoglobulin fusion proteins: The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and... Agent: Wood, Herron & Evans, LLP

20080292706 - Hydrogel composition and methods for making the same: The invention provides a hydrogel composition comprising water and a hydrophilic polymer, wherein the hydrogel composition has (a) an ultimate tensile strength of about 10 kPa or more, (b) a compressive strength of about 70 kPa or more, or (c) an ultimate tensile strength of about 10 kPa or more... Agent: Leydig Voit & Mayer, Ltd

20080292707 - Pharmaceutical compositions of adsorbates of amorphous drug: Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.... Agent: Pfizer Inc.

20080292708 - Polymeric adhesive matrix with salified carboxylic groups for transdermal use: Polymeric matrices for the controlled release of medicaments for the topical transdermal use comprising copolymers of acrylic and/or methacrylic acid or esters thereof having a Tg lower than 0° C., whose free carboxy groups are salified with compatible organic or inorganic bases. The matrices of the invention allow to prepare... Agent: Mcguirewoods, LLP

20080292709 - Kits for dhea and dhea-sulfate for the treatment of chronic obstructive pulmonary disease: Kits for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), or their salts, in an amount effective for preventing or treating COPD.... Agent: Wilson Sonsini Goodrich & Rosati

20080292710 - Liquid dosage forms of acid labile drugs: Liquid formulations of acid-labile drugs are provided. The formulations generally comprise micro-granules comprising an acid-labile drug coated with an enteric coating and a liquid vehicle having a pH less than 6.0. The components of the formulation can separately provided in the form of kits. The formulations and kits may be... Agent: Dykema Gossett PLLC

20080292712 - Methods and compositions for enhanced delivery of bioactive molecules: Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synthetic polymers such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and copolymers thereof. Bioactive molecules... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080292711 - Polysiloxane coated metal oxide particles: The invention provides novel coated metal oxide particles, wherein metal oxide particles are coated with a sunscreen on a polysiloxane basis with UV-A and/or UV-B and/or UV-C and/or broadband filter activity and a process for producing coated metal oxide particles and their use especially in cosmetic or dermatological formulations for... Agent: Nixon & Vanderhye, PC

20080292713 - Respirable powders: A spray dried dispersible powdered composition suitable for inhalation by a human subject, which composition comprises: a) at least one active agent suitable for treating a condition in said subject by inhalation; b) a hydrophobic amino acid; and c) a pharmaceutically acceptable biodegradable polymer.... Agent: Michael Best & Friedrich LLP

20080292714 - Bone targeting of degradable drug filled nanoparticles: This invention provides a method of modifying a cellular response in a mammal. The method comprises administering to the mammal an effective amount of biodegradable nanoparticles, each of said nanoparticles comprising an active agent, a biodegradable polymer, and a bone targeting agent administering to a mammal an effective amount of... Agent: Leydig Voit & Mayer, Ltd

20080292715 - Unique manuka factor (umf) fortified honey: The invention relates to UMF amended food stuffs and medicaments. In particular, although not exclusively, the invention relates to UMF fortified honey, methods for the preparation of UMF fortified honey, and methods for the preparation of UMF containing fractions of honey.... Agent: Knobbe Martens Olson & Bear LLP

20080292720 - Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal: Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with... Agent: Marshall, Gerstein & Borun LLP

20080292716 - Electrolytic water and process for production thereof: The present invention discloses a process for producing an electrolytic water, wherein a to-be-electrolyzed water containing less than 0.1 mM of a water-soluble inorganic salt, 0.05 to 0.5 mass % of a hydroquinone derivative and 1 to 50 mM of L-ascorbic acid or a derivative thereof is fed into a... Agent: Bruce S. Londa Norris Mclaughlin & Marcus, Pa

20080292717 - Highly stable aqueous solution, electrode with nanocoating for preparing the solution and method for making this electrode: A highly stable aqueous solution having a molecular cluster with dimensions which are small enough to ensure substantial chemical-physical stability thereof for a relatively long time. To prepare the solution a fluid treatment device is used, which comprises at least one chamber (7) and at least one anode (4) and... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20080292718 - Method for suppression appetite and food intake: The invention relates to method for suppressing appetite and food intake in a mammal in need thereof comprising a step of administering to said mammal an effective amount of water comprising from 99.76 to 99.99 molecular % of isotopologue 1H2160. Further, invention relates to medical food for suppressing appetite and... Agent: Notaro And Michalos

20080292719 - Method of treating metabolic syndrome: The invention relates to the method of treating metabolic syndrome in a mammal in need thereof comprising a step of administering to said mammal an effective amount of water comprising from 99.76 to 99.99 molecular % of isotopologue 1H216O. Further, invention relates to the medical food for treating metabolic syndrome... Agent: Notaro And Michalos

20080292723 - Bioactive acid agrichemical compositions and use thereof: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising metal-acid solutions.... Agent: Edward K. Welch Ii Ip&l Solution

20080292721 - Bioactive acid agrichemical compositrions and use thereof: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising metal-acid solutions.... Agent: Edward K. Welch Ii Ip&l Solution

20080292722 - Food preservation compositions and methods: A method of disinfecting surfaces said method comprising applying a disinfectant solution to surface to be disinfected and allowing the solvent to evaporate or wiping the excess solution from the surface after a period of time wherein the solution is an antimicrobial metal ion-acid solution.... Agent: Edward K. Welch Ii Ip&l Solution

20080292724 - Composition for improving membrane composition and functioning cells: the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin... Agent: Banner & Witcoff, Ltd.

20080292725 - Copper-free footbath blend: Provided is a composition suitable for treating a foot of an animal. The composition comprises zinc sulfate monohydrate, a chloride salt, and an acid, wherein the composition does not comprise copper. Also provided is a method for treating a foot of an animal. The method comprising contacting the foot of... Agent: Sonnenschein Nath & Rosenthal LLP

20080292726 - Ophthalmic gallium compositions and methods of their use: Provided are ophthalmic pharmaceutical compositions comprising gallium. These compositions are designed primarily for topical ocular and intraocular administration. Also provided are methods of use for the compositions in the treatment of human and veterinary diseases and disorders. Treatable diseases and disorders include adverse conditions of the eye and adnexal tissues... Agent: Lawrence R. Bernstein

20080292728 - Cosmetic composition: A cosmetic composition effective in skin lightening or skin rejuvenation is provided. The cosmetic composition is characterized by containing sodium ions, potassium ions, calcium ions, magnesium ions, chlorine ions and HCO3 ions in a molar concentration proportion equal to that in the extracellular fluid of mammals and further containing glucose... Agent: Bacon & Thomas, PLLC

20080292727 - Technique for treatment and prevention of fungal diseases in field-grown grains and legumes by application of acid-activated sodium chlorite solution: A technique for reducing fungal disease in growing grain-producing grasses and growing legume plants involves the generation of chlorine dioxide gas by dissolution of sodium chlorite with an activating acid in an aqueous solution, followed by foliar application of the gas to grasses or legume plants growing in fields. The... Agent: Hogan & Hartson LLP

20080292729 - Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment: Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilized chlorite solutions (e.g. WFIO) and a fluoropyrimidine, 5-FU, or a 5-FU prodrug (e.g. capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilized chlorite solution in combination with a fluoropyrimidine dramatically improves... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

20080292730 - Nutritional supplement for osteoarthritis: The present invention relates to a method of treating osteoarthritis by administering a mineral composition in the form of a nutritional supplement, where the mineral composition may contain Smectite, Gypsum, Quartz, Feldspar, Jarosite, Kaolinite and/or Zeolite.... Agent: Kramer & Amado, P.C.

20080292731 - Method for pain control: Methods for providing post-operative pain control or relief to a patient are disclosed. Methods include, for example, administering bicarbonate to an area of a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, in an area... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080292732 - Plant and plant storage organ having glp-1 derivative accumulated therein and method of producing the same: The present invention is to provide a plant and a plant storage organ thereof in which GLP-1 derivatives are accumulated, and a method of producing them in order to develop a method for ingesting orally GLP-1 derivatives at a low cost and to make use of it in diabetic treatment.... Agent: Foley And Lardner LLP Suite 500

20080292733 - Antioxidant and fe2+ chelating properties of herbal extracts: The present invention is directed to antioxidative and antiproliferative agents containing North American ginseng (proprietary extract HT1001) alone or in combination with Ginkgo biloba (GB), Saint John's Wort (SJW), ginkgolides, flavonoids, ginsenosides, hypericin, and/or hyperforin. The antioxidative and antiproliferative agents according to the present invention show significant inhibition of Fe2+-catalyzed... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080292734 - Compositions and methods for treatment of dermal scarring and wrinkling: Compositions and methods for treatment of dermal scarring and wrinkling, by application to the skin of a cosmetically effective amount of Plantago major or Plantago Lanceolata. The plantain may be utilized in powdered form in an aqueous paste or poultice, or in a crème base or ointment that is applied... Agent: Intellectual Property / Technology Law

20080292735 - Regulating alkaloids: MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression... Agent: Foley And Lardner LLP Suite 500

20080292736 - Bioavailability enhancing activity of carum carvi extracts and fractions thereof: The present invention relates to the use of extracts of Carum carvi as bioenhancers, either alone or in combination with piperine or Zingiber officinale extract to improve the bioavailability of a wide variety of drugs.... Agent: Ladas & Parry LLP

20080286197 - Antibody for diagnosing and treating neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders: An antibody for diagnosis or treatment of neuropsychiatric diseases, in particular schizophrenia, depression or bipolar affective disorders, is characterized in that the antibody recognizes misfolded specific proteins that can be assigned to one of the diseases, and a method for diagnosis by means of antibodies that bind to neuropsychiatric disease-specific... Agent: Rankin, Hill & Clark LLP

20080286199 - Methods of detecting ovarian cancer: The present invention provides methods of detecting ovarian cancer using biomarkers.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080286198 - Novel anti-igf-ir antibodies and uses thereof: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic... Agent: Buchanan, Ingersoll & Rooney PC

20080286200 - Lyophilized edible food incorporating a marker and methods of making: A standardized, lyophilized edible food containing a biologically safe stable marker for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient.... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20080286201 - Caspase-3 substrate comprising imaging agents: The present invention relates to diagnostic imaging agents for in vivo imaging. The imaging agents comprise a synthetic caspase-3 substrate peptide labelled with an imaging moiety suitable for diagnostic imaging in vivo. The invention also provides radiopharmaceutical compositions comprising the imaging agents, together with kits for the preparation of the... Agent: Ge Healthcare, Inc.

20080286202 - Method of diagnosing prodromal forms of diseases associated with amyloid deposition: A method of identifying a patient as prodromal to a disease associated with amyloid deposition by imaging techniques is provided. In addition, a method of identifying amyloid deposition diseases in patients who present with a dementing disorder of questionable etiology by imaging techniques is provided. The methods discloses substances which... Agent: Foley And Lardner LLP Suite 500

20080286203 - Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors: The present invention provides, inter alia, inhibitors of cardiovascular diseases and disorders. The present invention also provides therapeutic methods for preventing and/or treating cardiovascular diseases and disorders. Further, the present invention provides methods of identifying inhibitors of cardiovascular diseases and disorders as well as model systems suitable for identifying such... Agent: Pepper Hamilton LLP

20080286204 - Modulators of cftr: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20080286205 - Method for treating prostate diseases based on local delivery of active substances: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a... Agent: Thorpe North & Western, LLP.

20080286206 - Composition and method for medical imaging of body cavities: The present invention relates to an image enhancing composition for the enhancement of contrast in a body cavity, wherein the viscosity of the composition is between 2000 and 4000 mPa·sec. It also relates to a method for enhancing contrast of an image of a body cavity, which method involves introducing... Agent: The Webb Law Firm, P.C.

20080286208 - Eye treatment: The invention relates to a method of diagnosing the eye and to methods for subsequent treatment following such diagnosis. The method involves diagnosing a deficiency in the anatomy and performance of the upper eyelid recognizing the impact of this deficiency during blinking on problems such as dry eye, contact lens... Agent: Robert G. Rosenthal

20080286207 - Polycyclo dyes and use thereof: The invention relates to a family of fluorescent compounds that comprise a bridged polycyclo moiety. The compounds can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications, and are... Agent: Goodwin Procter LLP Patent Administrator

20080286209 - Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for consulsive seizure: Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure,... Agent: Bell, Boyd, & Lloyd LLP

20080286210 - Novel antimicrobial peptides: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.... Agent: Townsend And Townsend And Crew, LLP

20080286211 - Using mucin glycoproteins in combination with therapeutic agents to treat epithelial lesions and disorders of impaired mucin function: The present invention features methods of treating a patient having an epithelial lesion or disorder of impaired mucin function. The present invention further features methods of treating pain associated with epithelial lesions and disorders of impaired mucin function. Epithelial lesions and disorders of impaired mucin function can be treated using... Agent: Clark & Elbing LLP

20080286212 - Antimicrobial formulations and methods of using the same: Formulations and blends are described comprising zinc, silver, bismuth and copper in non-toxic amounts that are useful as treatments of a wide variety of conditions and diseases promoted by bacteria or other microorganisms.... Agent: Baker Botts, LLP

20080286213 - Pharmaceuticals for treating or preventing oral diseases: The present invention discloses morusin, a method of extracting morusin, as well as various uses in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses.... Agent: Baker & Mckenzie LLP

20080286214 - Stannous salt and sodium tripolyphosphate oral care compositions and methods: Oral care compositions containing a stannous salt and sodium tripolyphosphate are provided where stannous tripolyphosphate ionic intermediates comprise less than about 1% of the compositions Tetrasodium pyrophosphate, a methylvinyl ether-maleic anhydride copolymer and/or a silica oral polishing agent may be added for further efficacy. In a single phase blend, the... Agent: Colgate-palmolive Company

20080286215 - Method of preventing oral staining: A cosmetic method of preventing or decreasing oral staining, comprising the step of exposing the oral cavity to a morpholino compound having the general formula (I) wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080286216 - Surface active calcium phosphates: A nitrogen complex of an inorganic phosphate comprising the anionic sub-structure (I); whereby a nitrogen atom (N) of a complexing agent is complexed to an oxygen atom (O) of the inorganic phosphate; wherein the nitrogen atom is selected from the group consisting of a nitrogen atom of an amine group... Agent: Hahn Loeser & Parks, LLP

20080286217 - Sunscreen compositions and methods: Sunscreen compositions are provided for protecting skin from sun-induced damage comprising (i) at least one UV-B or UV-A/UV-B sunblock active, (ii) at least one meroterpene and (iii) a dermatological acceptable carrier. Preferably, the sunblock active will be a UV-A/UV-B sunblock active or said sunscreen compositions will further comprise at least... Agent: Edward K. Welch Ii Ip&l Solution

20080286218 - Cosmetic compositions containing at least one conditioning agent and at least one ethylene polymer with polyethylene glycol grafts: The invention concerns cosmetic compositions comprising: A) at least one conditioning agent selected among synthetic oils, mineral oils, vegetable oils, fluorinated and perfluorinated oils, natural or synthetic waxes, silicones, cationic polymers whereof the cationic filler density is less than 5 meq/g, cationic proteins, cationic protein hydrolysates, ceramide type compounds, cationic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080286219 - Hydroquinone derivative skin brightening compounds: Skin brightening compositions based on hydroquinone derivatives and methods of making and using the composition. The hydroquinone derivatives are 2-thio-hydroquinone derivatives.... Agent: Brett L. Nelson Eastman Chemical Company

20080286220 - Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions: The invention provides a hair treatment composition comprising i) a disaccharide; ii) a di-acid, and iii) a source of ammonium ions.... Agent: Unilever Patent Group

20080286221 - Anionic ethyl methacrylate copolymers and use thereof: The present invention relates to copolymers which comprise ethyl methacrylate, at least one α,β-ethylenically unsaturated amide group-containing compound and at least one monoethylenically unsaturated carboxylic acid in copolymerized form, to cosmetic and pharmaceutical compositions which comprise at least one such copolymer, and to the use of these copolymers.... Agent: Connolly Bove Lodge & Hutz, LLP

20080286222 - Oily solid cosmetics: e

20080286223 - Compositions having a high antiviral and antibacterial efficacy: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, and (c) water, wherein the composition has a pH of about 5 or less.... Agent: Marshall, Gerstein & Borun LLP (dial)

20080286224 - Use of a lotion composition on an absorbent article for reducing adherence of feces or menses to the skin: The present invention relates to lotion compositions comprised on a body facing surface of an absorbent article such as a diaper, training pants or adult incontinence product. The lotion composition reduces the adherence of feces or menses to the human skin. The lotion composition comprises at least two compounds wherein... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080286225 - Antimicrobial and antiviral product: An antimicrobial and/or antiviral polymer is provided. The polymer is a modified polymer of a precursor polymer that comprises nitrogen atoms. The precursor polymer is modified into the antimicrobial and/or antiviral polymer of the present invention by substituting at least part of the nitrogen atoms with a (C1-C20) alkyl group... Agent: Harness, Dickey & Pierce, P.L.C

20080286226 - Polymeric enhancement of pesticide bait sprays to increase rainfastness: An insecticide composition is provided for killing insects comprising a bait spray formulation comprising a bait component, an insecticide component, and an adjuvant effective to decrease the water solubility of the bait spray formulation upon drying of the bait spray formulation. Upon application to a target environment, the bait spray... Agent: Beusse Wolter Sanks Mora & Maire

20080286228 - Compositions and methods for enhancing immune responses mediated by antigen-presenting cells: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods... Agent: Dann, Dorfman, Herrell & Skillman

20080286230 - Compounds and pharmaceutical compositions for the treatment of viral infections: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.... Agent: Jones Day

20080286229 - Method to promote hair growth and/or delay or treat hair loss by administering a tgf-beta antagonist or inhibitor: The present invention provides methods for promoting hair growth and/or treating or preventing hair loss (alopecia) by contacting the cells with a TGF-β antagonist or inhibitor either alone or in combination with other alopecia-inhibiting compounds.... Agent: Elmore Patent Law Group, P.C.

20080286232 - Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080286231 - Novel inhibitors of glutaminyl cyclase: t

20080286227 - Use of il-17f for the treatment and/or prevention of neurologic diseases: The invention relates to the use of IL-17F, or of an agonist of IL-17F activity, for treatment or prevention of neurologic diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080286234 - Method for treating demyelinating diseases: A method for treating demyelinating diseases such as MS comprised of administering to an individual afflicted with a demyelinating disease a medicament that induces prolactin secretion. Prolactin secretion stimulates oligodendrocyte precurser cells, which remyelinate demyelinated nerve cells. The medicament is administered at a dosage sufficient to induce prolactin secretion resulting... Agent: Paul G. Lunn

20080286233 - Piperizinyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080286235 - Antimicrobials and related methods: Compositions for antimicrobial, antibacterial, antiviral, fungicidal and sporicidal applications comprise a mixture of alkyl betaine and alkyl amine oxide components together with a protonating agent. The compositions are particularly effective in the treatment and elimination of microorganisms in planktonic cell form as well as in sessile cell form in biofilms.... Agent: Lynn G. Foster

20080286239 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition... Agent: Townsend And Townsend And Crew, LLP

20080286236 - Inhibition of yersinia pestis: The disclosure relates to the targeting of Y. pestis mediated by the binding activity of tail fibers from naturally occurring R-type pyocins from Pseudomonas aeruginosa. The targeting may be mediated by a macromolecular complex such as the pyocin itself, a high molecular weight (hmw) bacteriocin modified to have the tail... Agent: Townsend And Townsend And Crew, LLP

20080286238 - Recombinant adenovirus expressing a gene encoding streptolysin o proetin and anti-cancer composition comprising same: A recombinant adenovirus expressing a streptolysin O (SLO) protein comprising a SLO gene; a promoter operably linked to the SLO gene; a polyadenylation signal sequence; and an adenovirus genome lacking E1 gene effectively kills a cancer cell by expressing a pore-forming toxin, SLO protein, and, therefore, is useful for the... Agent: Sughrue Mion, PLLC

20080286237 - Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.... Agent: Fulbright & Jaworski L.L.P.

20080286248 - Hiv vif mutants: A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 1A representing the Vif wild-type consensus sequence, are replaced with another amino acid, and wherein the nucleotide sequence does... Agent: Marshall, Gerstein & Borun LLP

20080286250 - Implantable biocompatible immunoisolatory vehicle for delivery of gdnf: The present invention relates to devices comprising a composition of human cells secreting a therapeutically effective amount of GDNF (Glial cell-line-derived neurotrophic factor) encapsulated in a device comprising a core and a semipermeable membrane allowing for the diffusion of GDNF protein. The human cells are from one cell line.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080286247 - Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene: A method for transducing a pathologic hyperproliferative mammalian cell is provided by this invention. This method requires contacting the cell with a suitable retroviral vector containing a nucleic acid encoding a gene product having a tumor suppressive function. Also provided by this invention is a method for treating a pathology... Agent: Townsend And Townsend And Crew, LLP

20080286249 - Use of mesenchymal stem cells for treating genetic diseases and disorders: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.... Agent: Mcandrews Held & Malloy, Ltd

20080286240 - Ecologically protected material: The present invention relates to an ecological protected material, comprising a base material (4) provided with a water-insoluble substance, a growth substrate and a microorganism layer. The invention further relates to a method for preparing a material according to the invention, comprising providing a base material with a water-insoluble substance,... Agent: Morrison & Foerster LLP

20080286251 - Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins: Described herein is a microbial composition used to enhance anti-cancer drugs. Specifically, microbial compositions that comprise a part of or an entire microorganism having surface lectins specific to carbohydrate moieties on tumor surface combined with an oncolytic agent.... Agent: Greenberg Traurig, LLP

20080286252 - Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same: The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.... Agent: Chalker Flores, LLP

20080286254 - Composition comprising licorice polyphenol: A composition containing a licorice polyphenol and other active ingredient (antioxidant ingredient, polyphenol other than licorice polyphenol or a component relating to lipid absorption or metabolism) is highly safe, can be produced easily, and can be utilized for foods and drinks such as health food, food with health claims (specified... Agent: Birch Stewart Kolasch & Birch

20080286253 - Composition comprising polymeric material and uses thereof: Compositions for the selective delivery of an agent comprising an uncrosslinked starch modified by an acidic group and an agent are described. The compositions are substantially resistant to degradation and thus result in no or substantially no release of the agent in a first environment, and are capable of degradation... Agent: Goudreau Gage Dubuc

20080286244 - Bio-artificial materials with tuneable properties: This invention relates to methods for preparing biomaterials by applying multiple cycles of tensile loading to compacted collagen gels in order to fuse the collagen fibrils together within the compacted gels. This produces a biomaterial with improved material properties. Biomaterials produced by such methods may be useful, for example, as... Agent: Klarquist Sparkman, LLP

20080286246 - Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient: Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or... Agent: Foley And Lardner LLP Suite 500

20080286243 - Method for isolation of a hair follicle stem cell and a composition for hair reproduction: The present invention relates to a method for isolating hair follicle stem cells and a composition for inducing hair growth. More specifically, relates to a method for isolating hair follicle stem cells showing a positive immunological response to CD34, by chemically degrading hair follicle-containing scalp tissue and then culturing the... Agent: Intellectual Property / Technology Law

20080286245 - Preparation of regulatory t cells using icam-1 co-stimulation: A method for generating a purified regulatory T cell composition having a CD4+CD25+Foxp3− phenotype from naive T cells having CD4+CD45RA+RO−CD11alo CD27+ phenotype comprising the steps of stimulating a T cell receptor on the naive T cells and stimulating ICAM-1 on the naive T cells.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080286241 - Transplantation of differentiated immature adipocytes and biodegradable scaffold for tissue augmentation: Provided is a technology involving differentiating preadipocytes, derived from human adipose tissues, into adipocytes and transplanting the differentiated adipocytes in conjunction with a biodegradable scaffold into the body. According to the present invention, when immature adipocytes having a cell diameter of 20 to 40 μm, obtained by differentiation of adipose... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080286255 - Treatment for eye disorder: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy... Agent: Fulbright & Jaworski, LLP

20080286256 - Methods and compositions for killing spores: The invention provides a sporocidal composition comprising a laccase or a compound exhibiting laccase activity, a source of oxygen and a source of iodide ions. A method of killing or inactivating spores and a method of decontaminating a location, which has been exposed to spores, are also disclosed.... Agent: Novozymes North America, Inc.

20080286257 - Compounds for use in treating abnormal cell proliferation, and methods of producing same: The invention relates to the modification of recombinant human lysozyme from genetic engineering (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating with typical linkers one or more out of the six free amino groups of the five lysines (K) present in the rHLys chain.... Agent: Standley Law Group LLP

20080286258 - Bifeprunox mesylate maintenance dose compositions and methods for using the same: The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080286259 - Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings: Major bleedings induced by thrombolytic/fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or a functional derivative thereof.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080286242 - Augmentation and repair of spincter defects with cells including mesenchymal cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, PLLC

20080286263 - Diagnosis of neurodegenerative diseases: The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being... Agent: Arent Fox LLP

20080286260 - Diagnostic and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara): The invention provides a human PPARA which is associated with the cardiovascular diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, gastroenterological diseases, cancer, inflammation, hematological... Agent: Banner & Witcoff, Ltd.

20080286267 - Methods for treating nervous system inquiry and disease: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent... Agent: Linda O. Palladino

20080286261 - Methods of modulating hair growth: The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride.... Agent: Fish & Richardson PC

20080286264 - Modulation of muc1 activity: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUC1 by a cell.... Agent: Fulbright & Jaworski L.L.P.

20080286266 - Novel use of il-1beta compounds: This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1... Agent: Novartis Corporate Intellectual Property

20080286262 - Photosensitizers for photodynamic therapy at infrared excitation: A photosensitizer that is excitable via infrared radiation and is adapted to be used to treat a selected biological target. The photosensitizer comprises a core nanoparticle adapted to convert infrared radiation into a visible light emission, and a coating disposed about the core nanoparticle. The coating contains a light excitable... Agent: Robert W. Becker & Associates

20080286268 - Processed ecm materials with enhanced component profiles: Described are medical graft materials and devices having improved properties relating to their component profiles.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080286265 - Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent: Philip S. Johnson Johnson & Johnson

20080286269 - Anti-alpha(v)beta(6) antibodies and uses thereof: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of... Agent: Howrey LLP - Dc

20080286272 - Epha3 antibodies for the treatment of solid tumors: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.... Agent: Townsend And Townsend And Crew, LLP

20080286273 - Knowledge-based proliferation signatures and methods of use: The present invention provides methods and compositions for predicting patient responses to cancer treatment using a proliferation gene signature. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for... Agent: Siemens Corporation Intellectual Property Department

20080286271 - Methods and compositions for modulating tweak and fn14 activity: Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases.... Agent: Genentech, Inc.

20080286270 - Stabilized liquid anti-rsv antibody formulations: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof,... Agent: Jones Day

20080286274 - Vector for efficient selection and/or maturation of an antibody and uses thereof: It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.... Agent: Steinfl & Bruno

20080286277 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080286275 - Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.... Agent: Merck And Co., Inc

20080286276 - Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (prrsv): The present invention provides a purified preparation containing, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), antigenic regions of such proteins which are at... Agent: Bingham Mccutchen LLP

20080286278 - Process for in vivo treatment of specific biological targets in bodily fluids: A process for treating biological targets in a fluid of a biological organism, including introducing a fluid comprising a biological target to an assembly comprising an inlet connected to receive the fluid and an outlet connected to pass the fluid from the assembly, wherein the assembly comprises a flow chamber... Agent: Buchanan, Ingersoll & Rooney PC

20080286280 - Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies: The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080286279 - Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi): Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses... Agent: Novartis Vaccines And Diagnostics Inc.

20080286281 - Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation: Administration of monoclonal antibodies specific for IL-2R to xenograft recipients, or long-term to immunosuppression-intolerant or non-compliant patients over a period of time beyond the very early phase of organ transplantation, prevents transplant rejection.... Agent: Novartis Corporate Intellectual Property

20080286282 - Novel use of sulfonamide compound in combination with angiogenesis inhibitor: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.... Agent: Birch Stewart Kolasch & Birch

20080286283 - Treatment of cancer with antibodies to costimulating polypeptide of t cells: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or... Agent: Jones Day

20080286284 - Compositions of psma antibodies: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof... Agent: Progenics Pharmaceuticals, Inc. C/o Wolf, Greenfield & Sacks, P.C.

20080286285 - Methods for treating vascular disease: Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88). TLR4 cell... Agent: Davis Wright Tremaine LLP/los Angeles

20080286287 - Methods and agents for modulating cellular activity: The present invention discloses the use of modified IGFBP-2 and agents that regulate the interaction between HBD of IGFBP-2 and EC or PC matrix components to prevent cellular proliferation invasion and/or migration (metastases).... Agent: Knobbe Martens Olson & Bear LLP

20080286286 - Methods to treat disease states by influencing the signaling of ox-40-receptors and high throughput screening methods for identifying substances therefor: OX40L inhibits the generation of IL-10-producing Tr1 cells from naïve and memory CD4+ T cells induced by the immunuosuppressive drugs dexamethasone and vitamin D3. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. OX40L also strongly inhibits the generation of IL-10-producing Tr1... Agent: Bracewell & Giuliani LLP

20080286289 - Use of b cell expansion agents in generating antibodies: A method for efficiently generating antibodies immunizes an animal with a target antigen and a B cell expansion agent, such as an anti-CD40 agonist. The antibodies generated from this method are useful as therapeutic agents, diagnostic agents or research reagents in a variety of diseases and conditions.... Agent: Philip S. Johnson Johnson & Johnson

20080286288 - Vascular endothelial growth factor 2: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080286290 - Anti-cd14 antibody fusion protein: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.... Agent: Birch Stewart Kolasch & Birch

20080286291 - Betulinol derivatives as anti-hiv agents: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject... Agent: Marshall, Gerstein & Borun LLP

20080286292 - Molecular vaccine linking intercellular spreading protein to an antigen: Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a... Agent: Foley Hoag, LLP (w/jhv)

20080286293 - Promiscuous pap cd4 t cell epitopes: The present invention relates to the discovery of novel T cell epitopes of the human prostatic acid phosphatase (PAP) protein that is promiscuous for at least 15 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such an... Agent: Townsend And Townsend And Crew, LLP

20080286294 - Nodavirus-vlp immunization composition: The present invention relates to an immunogenic composition for fish comprising nodavirus virus-like particles (VLPs) formed with nodavirus capsid protein assembly, for use as a vaccine. This composition is suitable for administration to fish via the intramuscular or intraperitoneal route, or by bath and/or via the oral route. The invention... Agent: Foley And Lardner LLP Suite 500

20080286295 - Use of recombinant antigens to determine the immune status of an animal: The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent, under conditions suitable for formation... Agent: Heska Corporation Legal Department

20080286296 - Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080286297 - Chimeric carrier molecules for the production of mucosal vaccines: The invention relates to a protein complex for the delivery of an antigen to and across mucosal surfaces and the production of said complex in a host cell, such as a plant. Provided is a protein complex comprising at least two, preferably identical, subunits wherein at least one subunit is... Agent: Hoffmann & Baron, LLP

20080286298 - Compositions comprising hypsizygus ulmarius extract: Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1β mediated adhesion of polymorphonuclear leukocytes. The hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts.... Agent: The Estee Lauder Cos, Inc

20080286299 - Film-forming resins as a carrier for topical application of pharmacologically active agents: The invention provides a biological dressing for treatment of a dermatological disease comprised of one or more resins or other film-forming agents, a topically acceptable volatile solvent, and a pharmacologically active agent. The combined one or more resins are present in a suitable amount such that the composition, when the... Agent: Dla Piper US LLP

20080286300 - Analysis of saccharide vaccines without interference: The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to... Agent: Novartis Vaccines And Diagnostics Inc.

20080286301 - Treatment of diabetes: e

20080286302 - Safe mutant viral vaccines: The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation... Agent: Pharmacia & Upjohn

20080286303 - Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease: A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to... Agent: Robert Yoshida Sanofi Pasteur Inc.

20080286305 - Antigen transduced t cells used as a delivery system for antigens: A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.... Agent: Marshall, Gerstein & Borun LLP

20080286304 - Modifying leukocyte function: Use of PREPS and/or L-particles for the manufacture of a medicament for modifying or regulating leukocyte function.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080286306 - Hiv vaccines based on env of multiple clades of hiv: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another... Agent: Knobbe, Martens, Olson & Bear, LLP

20080286307 - Two-step temperature profile for the propagation of viruses: The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual... Agent: King & Spalding

20080286308 - Pathogenic bovine enterovirus, vaccines, and diagnostic methods: The isolation of a novel pathogenic bovine enterovirus is described. The novel pathogenic bovine enterovirus is used to develop antibodies and immunogenic compositions against the novel pathogenic bovine enterovirus. Diagnostic assays are described.... Agent: Novartis Animal Health US Inc.

20080286309 - Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli: A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (ΔSpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080286310 - Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic escherichia coli in cattle: The invention provides live, attenuated enterohemorrhagic Escherichia coli (EHEC) bacteria in which the Shiga toxin coding sequences are deleted to abolish Shiga toxin production and one or more of the nucleotide sequences for the bacterial adhesin protein intimin, the locus of enterocyte effacement encoded regulator, and the translocated intimin receptor... Agent: Coleman Sudol Sapone, P.C.

20080286311 - Protein allergen derivatives: The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or... Agent: Chalker Flores, LLP

20080286314 - Dendritic cells loaded with heat shocked melanoma cell bodies: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.... Agent: Chalker Flores, LLP

20080286312 - Membrane-anchored beta2 microglobulincovalently linked to mhc class i peptide epitopes: The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080286315 - Methionine enkephalin as an adjuvant for vaccine immunizations: The present invention provides a method of stimulating dendritic cells, comprising contacting the dendritic cells with methionine enkephalin. The present invention also provides methods of enhancing an immune response to an antigen in a mammal. In a first method, dendritic cells are isolated from the mammal. The dendritic cells are... Agent: Peters Verny , L.L.P.

20080286313 - Peptide vaccines for the treatment of cancers: e

20080286316 - Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods: The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane... Agent: Jacqueline E. Hartt, Ph.d Allen, Dyer, Doppelt, Milbrath & Gilchrist, P.A.

20080286318 - Oral care compositions: An oral care composition containing polymeric microparticles highly loaded with an oral care compound is disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080286317 - Self-adhesive film for teeth: Monolayered or multilayered, film-shaped, pressure-sensitive adhesive preparations for application in the oral region and a process for manufacturing such preparations. The preparations contain at least one polymethyl vinyl ether-maleic acid anhydride copolymer, polyvinyl acetate and/or at least one copolymer of the polyvinyl acetate with vinyl alcohol esters of fatty acids,... Agent: D. Peter Hochberg Co. L.p.a.

20080286320 - Absorbent article comprising a lotion composition for reducing adherence of feces or menses to the skin: The present invention relates to lotion compositions comprised on a body facing surface of an absorbent article such as a diaper, training pants or adult incontinence product. The lotion composition may be used for reducing the adherence of feces or menses to the human skin. The lotion composition comprises at... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080286319 - Antimicrobial surfaces and methods for preparing antimicrobial surfaces: The present invention relates to biocidal articles. In an embodiment the biocidal article comprises a plurality of polymers having biocidally active groups. The polymers are attached to a surface and may have a polydispersity less than 3. The biocidally active groups may comprise at least one of a quaternary ammonium... Agent: Jesse A. Hirshman, Esq.

20080286322 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: Nutter Mcclennen & Fish LLP

20080286321 - Polymer no donor predrug nanofiber coating for medical devices and therapy: The present invention relates to nanofibers that produce therapeutic amounts of nitric oxide after a delay period, which allows time to install or implant the device into a patient. The nitric oxide release is thus localized to the area of the organism where NO dosing is indicated. The delay time... Agent: Roetzel And Andress

20080286331 - Composition for an injectable bone mineral substitute material: The invention refers to an injectable composition for a bone mineral substitute material, which comprises a dry powder mixed with an aqueous liquid. The powder comprises a first reaction component comprising a calcium sulphate hemihydrate with the capability of being hardened to calcium sulphate dihydrate when reacting with said aqueous... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080286325 - Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent: The present disclosure provides methods of measuring the release of a taxane therapeutic agent from a medical device as a function time in contact with a suitable elution medium. The method preferably comprises the step of contacting a coated medical device comprising a taxane therapeutic agent with an elution medium... Agent: Brinks Hofer Gilson & Lione/indy/cook

20080286323 - Human therapeutic cells secreting nerve growth factor: The present invention relates to human cell lines genetically modified to overexpress bioactive NGF. In another aspect the present invention relates to encapsulated human cell lines genetically modified to overexpress bioactive NGF, which can be used in therapy of Alzheimer's disease, peripheral neuropathy and other neurological disorders amenable to local... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080286328 - Implant and production method for said implant: The invention relates to an implant, e.g. a stent, bone replacement material, a prosthesis, a scaffold or similar, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate)... Agent: Sughrue Mion, PLLC

20080286324 - Media and devices for cold storage of therapeutic cells: The invention provides a composition for cold storage of cells which includes a population of isolated stem cells, a cell medium, and isolated trophic factors, as well as devices having a plurality of the trophic factors.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080286326 - Medical devices having antifouling character: According to an aspect of the invention, medical devices are provided which include (a) a substrate and (b) a coating that includes an antifouling copolymer, an adhesive copolymer, or both. Antifouling copolymers for use in conjunction with the present invention contain (i) at least one antifouling polymer block having multiple... Agent: Mayer & Williams PC

20080286329 - Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration... Agent: The Webb Law Firm, P.C.

20080286330 - Methods and device to neutralize soluble toxic agents in the brain: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include Aβ, and the methods, agents and devices are useful for reducing the accumulation of Aβ, which is a principal constituent of the plaques associated with such diseases as... Agent: Campbell Nelson Whipps, LLC

20080286327 - Thombolysis and chronic anticoagulation therapy: Method and systems of treating a patient with at least one of a myocardial infarction, a stroke, and a pulmonary embolism include providing a stimulator coupled to at least one electrode and a catheter, configuring one or more stimulation parameters to treat at least one of a myocardial infarction, a... Agent: Advantedge Law Group , LLC

20080286332 - Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties: The present invention relates to implantable medical devices coated with phosphoryl choline acrylate polymer topcoat layer, an acrylate copolymer layer containing a therapeutic agent, and their use in the treatment of vascular diseases.... Agent: Squire, Sanders & Dempsey LLP

20080286333 - Medical devices having coating with improved adhesion: According to an aspect of the present invention, a medical device is provided which comprises a metallic substrate and polymeric region disposed over and in contact with the metallic substrate. The polymeric region comprises (a) a block copolymer that comprises (i) a hard polymer block that comprises a high Tg... Agent: Mayer & Williams PC

20080286335 - Enhancement of the calcium sensing receptor: The disclosure relates to medical devices capable of enhancing ossification in a subject. More specifically, the disclosure relates to the use of devices comprising a releasable calcium sensing receptor agonist and a releasable calcium salt.... Agent: Norman F. Hainer, Jr. Smith & Nephew, Inc.

20080286334 - Ocular implant made by a double extrusion process: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.... Agent: Allergan, Inc.

20080286336 - Ocular implant made by a double extrusion process: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.... Agent: Allergan, Inc.

20080286338 - Drug delivery system with scleral lens: A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral... Agent: Wilmerhale/boston

20080286337 - Method of treating a disease in an eye using a scleral lens: A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral... Agent: Wilmerhale/boston

20080286339 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: Nutter Mcclennen & Fish LLP

20080286341 - Buffered coated nicotine containing products: Coated oral dosage forms for the delivery of nicotine in any form to a subject by rapid intraoral delivery of nicotine comprising at least one core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additives, wherein... Agent: Philip S. Johnson Johnson & Johnson

20080286340 - Buffered nicotine containing products: A pharmaceutical oral formulation for delivering nicotine in any form to a subject by transmucosal uptake in the oral cavity comprising nicotine in any form, wherein said oral formulation is buffered with at least one amino acid, preferably at least one endogenous amino acid. Also contemplated is a method for... Agent: Philip S. Johnson Johnson & Johnson

20080286342 - Form of administration based on crosslinked hydrophilic polymers: The invention relates to a film-shaped form of administration for topically administering at least one agent and/or nutrient to a living being. Said form of administration comprises at least one agent-containing and/or nutrient-containing layer that is based on crosslinked hydrophilic polymers which are crosslinked with at least one polyacrylic acid... Agent: Frommer Lawrence & Haug

20080286343 - Solid form: A solid form comprising at least one film enrobing a compacted fill material having at least one active material contained in a matrix and having low friability, a density of at least 0.5 g/ml based on the total solid volume of the solid form and a tensile strength less than... Agent: Patent Administrator Fmc Corporation

20080286344 - Solid form: s

20080286345 - Modified multilayered film: A composition for delivery of a molecule into a cell is provided. The composition includes a protein transduction domain that is conjugated to the molecule which is incorporated into a multilayered film. Preferably, the protein transduction domain is a cationic protein transduction domain. More preferably, the cationic protein transduction domain... Agent: Warf/bhgl

20080286347 - Bioabsorbable synthetic nonwoven fabric holding thrombin: A safe and effective hemostatic is provided. The invention relates to a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient and a hemostatic comprising said bioabsorbable synthetic nonwoven fabric. The bioabsorbable synthetic nonwoven fabric holding thrombin in accordance with the present invention may be prepared by a process... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080286346 - Wound dressing: A wound dressing comprises a support provided with a first side which is oriented towards the surface which is to be treated and a second opposite side, the support comprising a metal having an antimicrobial effect. A least the first side of the support has a preparation for localized therapy.... Agent: Dreiss, Fuhlendorf, Steimle & Becker

20080286348 - Secured transdermal delivery system: A secured transdermal delivery system, applicable to both matrix and reservoir patches, for preventing misuse of medications embedded within and affixed to transdermal patches. The secured transdermal delivery system includes a backing supporting a pharmaceutical composition and one or more security agents adapted to modify the pharmacophore of the pharmaceutical... Agent: General Counsel, P.C.

20080286349 - Systems, devices, and methods for passive transdermal delivery of active agents to a biological interface: Systems, devices, and methods for transdermal delivery of one or more therapeutic active agents to a biological interface. A transdermal drug delivery system is provided for passive transdermal delivery of one or more ionizable active agents to a biological interface of a subject. A transdermal drug delivery system includes a... Agent: Seed Intellectual Property Law Group PLLC

20080286353 - Cationic liposomes containing immune response generating moieties: Cationic liposomes with entrapped polynucleotide in the intravesicular space are described. The liposomes include cationic components such as cationic lipids such as DOTAP. Preferably the method of forming liposomes uses the dehydration-rehydration method in the presence of the polynucleotide. The polynucleotide preferably operatively encodes an antigen capable of eliciting a... Agent: Morrison & Foerster LLP

20080286350 - Formulation of multivalent antibody constructs and use of same for cancer therapy: The invention relates to the formation of multivalent antibody constructs for testing and therapeutic purposes. In one embodiment the constructs consist of antibodies or antibody fragments conjugated to liposomes. The constructs are employed in a cell-based in vitro assay for comparing the therapeutic activity of antibodies or antibody fragments in... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080286352 - Liposome compositions: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes and/or liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made... Agent: Novartis Corporate Intellectual Property

20080286351 - Pegylated cardiolipin analogs, methods of synthesis, and uses thereof: The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and/or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active... Agent: Neopharm, Inc.

20080286354 - Composition and therapies for hyperlipidaemia-associated disorders: The invention relates to pharmaceutical compositions comprising at least one fibrate and at least one bile acid, and to methods for the treatment of hyperlipidaemia or elevated liver function tests in a patient by administering at least one fibrate and at least one bile acid to the patient.... Agent: Bozicevic, Field & Francis LLP

20080286356 - Pharmaceutical compositions containing terbinafin and use thereof: Pharmaceutical compositions for oral administration comprising terbinafine and a method for administering high dosages while minimizing effects associated with e.g. a high dosage load, e.g. coated tablets or multiparticulate formulations such as minitablets or pellets, e.g. in capsules.... Agent: Novartis Corporate Intellectual Property

20080286355 - Protease inhibitors for the treatment of digestive pathologies: The invention relates to compositions and methods for the treatment of intestinal pathologies. The invention also relates to compositions and methods which can be used to regulate the paracellular permeability of the intestinal epithelium. The inventive compositions and methods are based in particular on the use of protease inhibitors which... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080286357 - Multi-functional particulate delivery system for pharmacologically active ingredients: The present invention relates to a pharmacologic dosage unit which includes a multi-functional particulate system and a pharmacologically active agent. The multi-functional particulate system includes solid biologically-safe particles incorporated into a matrix and having a characteristic that each individual particle retains its original size. The invention also relates to methods... Agent: Hoffmann & Baron, LLP

20080286358 - Wake up on time dietary supplement and method of use: A time-released dietary supplement is disclosed. The dietary supplement is meant be taken upon going to bed in the evening. The active ingredients are released during the night so the person will wake up energized and refreshed.... Agent: Arthur M. Peslak, Esq. Mandel & Peslak, LLC

20080286359 - Low dosage forms of risedronate or its salts: Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080286360 - Chemically patterned hydrogels, manufacture and use thereof: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the... Agent: Woodcock Washburn LLP

20080286367 - Compositions containing benefit agent composites pre-emulsified using colloidal cationic particles: A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof; and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of... Agent: Marshall, Gerstein & Borun LLP

20080286362 - Compositions exhibiting improved flowability: Powder compositions exhibiting improved flow properties. The compositions generally contain a bulk solid material in the form of a powder and surface-modified nanoparticles. Methods of improving the flow of powder compositions and devices and articles made using such compositions are also disclosed.... Agent: 3m Innovative Properties Company

20080286366 - Delivery of micro- and nanoparticles with blood platelets: The invention is directed to platelets containing micron or nanometer size particles wherein the micron or nanometer sized particles comprises an active agent. The invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the above platelets. The invention is further directed to methods of delivering... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080286364 - External dermatologic preparation: An object of the present invention is to provide an external dermatologic preparation which comprises nanoparticles consisting of proteins that can exhibit desirable effects via regulation of particle diameters. The present invention provides an external dermatologic preparation which comprises protein nanoparticles containing an active ingredient and having an average particle... Agent: Sughrue Mion, PLLC

20080286361 - Gene delivery: The present invention relates to a method of delivery of a therapeutic agent to a target cell the method comprising targeting particles comprising the therapeutic agent to the cell using magnetic means to apply a magnetic force to said particles so as to tend to move said particles towards said... Agent: Speckman Law Group PLLC

20080286365 - Method for producing solid-lipid composite drug particles: A method of producing solid composite lipid/drug nanoparticles that includes the steps of: (1) dissolving a lipid and a drug in a suitable organic solvent to form a solution; (2) emulsifying the solution in a liquid to form an emulsion having a discontinuous phase of micelles comprising the organic solvent,... Agent: Rankin, Hill & Clark LLP

20080286368 - Pharmaceutical composition for the treatment of acute disorders: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active... Agent: Morgan Lewis & Bockius LLP

20080286363 - Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases: p

20080286370 - Nanoscale particles used as contrasting agents in magnetic resonance imaging: The invention relates to nanoscale particles as contrast agents for magnetic resonance imaging, consisting of a core having an inert matrix, one or more covalently bonded organic complexing agents in which one or more metal ions having unpaired electrons are bonded, and optionally one or more biomolecules covalently bonded to... Agent: Millen, White, Zelano & Branigan, P.C.

20080286369 - Process for preparing microcrystals: This invention relates in general to micron or sub-micron particles comprising one or more water-soluble crystals wherein the crystals have a surface coating comprising one or more bioactive molecules as well as efficient methods of forming such particles and rapid methods for screening preferred conditions to form such particles. The... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080286371 - Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica: The present invention relates to a product named “immunogenical complex”, which comprises an adjuvant characterized by solid particles of highly ordinated nanostructured mesoporous silica, preferably, SBA-15 Silica, and vaccinal antigens of several natures, encapsulated in the referred to adjuvants. The immunogenical complex of the present invention allows the presentation of... Agent: Birch Stewart Kolasch & Birch

20080286372 - Therapeutic compositions for targeted vessel delivery: Methods for treating a vascular disease by delivering therapeutic compositions with enhanced endothelium targeting are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20080286373 - Ziprasidone formulations: the formulation further comprising (c) at least one surfactant selected from anionic and non-ionionic surfactants and still further comprising (d) at least one hydroxylalkyl alkylcellulose in which each alkyl group and each hydroxyalkyl group independently has from 1 to 4 carbon atoms. The formulation achieves improved dissolution and bioavailability of... Agent: Irving M. Fishman C/o Cohen Tauber Spievack & Wagner

20080286374 - Hollow nano-particles and method thereof: The invention provides a hollow nano-particle comprising a crosslinked shell and a void core; and a preparation method thereof. The hollow nano-particle may be used in rubber composition, tire product, and pharmaceutical delivery system etc.... Agent: Bridgestone Americas Holding, Inc.

20080286376 - Dry hemostatic compositions and methods for their preparation: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has... Agent: Baxter Healthcare Corporation

20080286375 - Method for preparing sustained-release microparticles comprising sucrose acetate isobutyrate: A sustained release microparticles which is capable of releasing a protein drug continuously over a long period of time without initial burst release of the drug can be simply prepared by a method including the steps of a) dissolving a protein drug in an aqueous solution to obtain a water... Agent: Sughrue Mion, PLLC

20080286377 - Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts: Anti-resorptive bone cements, comprising an anti-resorptive amount of one or more anti-resorptive agents, preferably the anti-resorptive agent is a bisphosphonate. The anti-resorptive bone cements are useful for reducing bone voids and bonding prosthetic devices to bone. The invention also relates to anti-resorptive allogeneic, autografic, and xenografic bone grafts, which bone... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20080286378 - Use of amniotic fluid (af) in treating ocular disease and injury: Compositions and methods for the treatment of ocular disease and injury are provided. The methods involve the administration of amniotic fluid directly to the eye, for example, as eye drops. The types of diseases and injuries that can be treated in this manner include chemical burns, dry eye and corneal... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080286379 - Method and means for obtaining platelet-rich plasma: Method and means for obtaining thrombocyte-rich plasma (platelet-rich plasma, PRP) from whole blood which specifically has a high content of specifically activated thrombocytes and which is particularly easy to coagulate.... Agent: Harness, Dickey & Pierce, P.L.C

20080286380 - Micronized wood preservative formulations: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic biocide comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic biocide... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080286381 - Anti-tumor drug, medicament, composition, and use thereof: An active polypeptide includes the amino acid sequence of SEQ ID NO:3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:3, or fragments thereof having at least 20 contiguous amino acids, or peptides having at least 50%, preferably 70%,... Agent: Young & Thompson

20080286382 - Compositions and methods for establishing and/or maintaining pregnancy: The present invention relates to compositions comprising selenium (e.g., organic selenium (e.g., selenized yeast (e.g., SEL-PLEX))) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment). For example, the present invention provides compositions comprising selenium (e.g., organic selenium (e.g., selenized yeast (e.g., SEL-PLEX))) and methods of using... Agent: Casimir Jones, S.c.

20080286383 - Soluble biogenic silica and application using same: A process of preparing a biogenic silica comprising the steps of incinerating a silica bearing organic source at a temperature up to 1200° C. and allowing the incinerated silica organic source to cool; adding the incinerated and cooled silica bearing organic source to an alkaline solution that has either been... Agent: Young & Thompson

20080286385 - Method of obtaining avocado powder: The invention relates to avocado powder and to the method of obtaining the same. Avocado powder is a novel product which enables the avocado to be preserved for an extended period of time at ambient temperature, such as to conserve the characteristic properties of the product, with the additional advantage... Agent: Miller, Matthias & Hull

20080286386 - Na+, k+-atpase expression in cervical dysplasia and cancer: The present disclosure provides methods of diagnosing cervical dysplasia and cervical cancer by detecting Na+, K+-ATPase expression. For example, it is demonstrated herein that expression of the Na+, K+-ATPase β1-subunit increases in cervical dysplasia and cervical cancer, relative to normal cervical tissue. Also provided are methods of treating cervical dysplasia... Agent: Klarquist Sparkman, LLP

20080286384 - Topical wound care product containing hyssop: A composition for treating wounds having an effective amount of hyssop extract, combined with glycerol, salt, saccharides, and water has been discovered to be effective in promoting healing of wounds.... Agent: Michael Best & Friedrich LLP

20080286387 - Standardized method for recovering enriched indian date extract (ide), properties of ide and applications thereof: Disclosed are (i) a standardized method for the recovery of the polyphenolic contents from the seed coats of Tamarindus indica L. (ii) a standardized polyphenolic extract (10%-90%) from the seed coat of Tamarindus indica L. (standardized Indian date extract) and uses thereof as oral/topical, “skin care” and “hair care” nutra-cosmetic... Agent: Sabinsa Corporation

20080286388 - Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salts and coffeine: Pharmaceutical composition and food comprising edible carboxylic acid and/or its acidic salt and optionally caffeine, crude drug and pharmaceutical acceptable carrier are disclosed. The invention also discloses the use and method of composition or food. The composition or food of the present invention can prevent, treat or relief allergy, ache,... Agent: Shin-jen Shiao

20080286389 - Processes of making north american ginseng fractions, products containing them, and use as immunomodulators: The invention is directed to chemical processes of preparing fractions form North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080286390 - Skin care composition: The skin care composition is a cream or lotion that moisturizes the skin, relieving dryness, itchiness, and eczema. The skin care composition contains moisturizers and a plurality of natural oils containing essential fatty acids, the natural oils being selected from the group consisting of borage oil, omega-3 oil, emu oil,... Agent: Litman Law Offices, Ltd.

20080286391 - Method for preparing ginkgo extracts having a low content of 4'-o-methyl pyridoxine and/or biflavones: The present invention relates to an improved multi-step method for preparing an extract from ginkgo biloba having a reduced content of 4′-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on... Agent: Edwards Angell Palmer & Dodge LLP

20080286392 - Body fat-reducing agent: The present invention provides a body fat-reducing agent containing a processed pueraria flower as an active component. The body fat-reducing agent has a superior body fat-reducing effect. Furthermore, the body fat-reducing agent may contain at least one of a lipid absorption suppressing component and a lipid metabolism promoting component. A... Agent: Amin, Turocy & Calvin, LLP

20080286393 - Method for the enrichment of the polyphenolic contents from unripe fruit rinds of terminalia belerica and uses thereof: An improved method for concentrating/enriching the polyphenolic contents from the dried, unripe fruit rinds of Terminalia belerica is disclosed. The present invention also discloses a light colored, enriched/concentrated (85%-100%) polyphenolic extract from the dried, unripe fruit rinds of Terminalia belerica which, by virtue of its excellent skin lightening, anti-aging, anti-inflammatory,... Agent: Sabinsa Corporation

20080286394 - Novel herbal formulation as brain tonic: The invention provides a novel herbal formulation used to improve the memory and in treatment of amnesia as a brain tonic. Formulation(s) comprises of oleaginous oil of Sesamum indicum and the alcoholic extract of Centella asiatica. Conventionally used as emulsion or as a soft gelatin capsule for oral dosage forms.... Agent: Merchant & Gould PC

20080279764 - Method and composition for treating cancer: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or a human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080279765 - Novel imaging agents for fibrosis: The present invention provides a novel imaging agent targeting the mannose-6-phosphate (M6P) receptor suitable for the non-invasive visualization of fibrosis. A method for the preparation of the imaging agent is also provided by the invention, as well as a precursor for use in said method. The invention also provides a... Agent: Ge Healthcare, Inc.

20080279766 - Methods for diagnosis and intervention of hepatic disorders: The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with... Agent: Faegre & Benson LLP Patent Docketing

20080279767 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20080279768 - Bifunctional metal chelating conjugates: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostics or therapeutic agents. Specifically, conjugates of the present invention include a carrier, a metal coordinating moiety, and a urea linkage chemically linking the metal coordinating moiety to the carrier. The carrier is generally utilized for targeting... Agent: Mallinckrodt Inc.

20080279769 - Enzyme inhibitor imaging agents: The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.... Agent: Ge Healthcare, Inc.

20080279770 - Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexes: The aim of the invention is to provide radiolytically and metabolically stable metal complexes suitable for conjugation with biomolecules and, therefore, useful for nuclear medical diagnostics and in endoradionuclide therapy and to provide a method for their production. This is achieved by metal complexes based on tetrathiol ligands of formula... Agent: Jordan And Hamburg LLP

20080279772 - Methods for detecting pathological sites: The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight... Agent: Wilmerhale/new York

20080279771 - Novel imaging agents for cancer: A novel imaging agent is described which comprises a semaphorin moiety and an imaging moiety. The novel imaging agent of the invention may be used in the diagnostic imaging of cancer and in particular, for targeting angiogenesis or metaplasia. Further aspects of the present invention presented herein include a method... Agent: Ge Healthcare, Inc.

20080279773 - Skeletal-targeted radiation to treat bone-associated pathologies: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20080279774 - Perturbed membrane-binding compounds and methods of using the same: The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.... Agent: Pearl Cohen Zedek Latzer, LLP

20080279775 - Benztropinamine analogs as dopamine uptake inhibitors: Disclosed are benztropinamine analogs having the formula I (I) in which E is NR1, S, or CH2; B is NR4, O, or CH2; m=1 to 5; n=1 to 3; Ar is a C5-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl group having 2 to 6... Agent: Leydig, Voit & Mayer, Ltd.

20080279777 - Compositions that include a hydrophobic compound and a polyamino acid conjugate: Various compositions that include a hydrophobic compound and a polyamino acid conjugate are prepared. The compositions described herein are useful for a variety of drug, biomolecule, and imaging agent delivery applications.... Agent: Knobbe Martens Olson & Bear LLP

20080279776 - Photosensitizers and mri enhancers: The present invention further relates to a compound of formula 3 or a salt thereof, linked or attached to a magnetic element. Such a compound may be used as an MRI enhancer. The present invention also relates to a method of carrying out an MRI scan using such an MRI... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080279778 - Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs: Various biodegradable polyglutamate conjugates comprising recurring units of the general formulae (I), (II), (III), (IV), (V), and/or (VI) are prepared. The polymers are conjugated with a plurality of drugs. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications.... Agent: Knobbe Martens Olson & Bear LLP

20080279781 - Glycosylated carboranylporphyrins and uses thereof: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity glycosylated carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20080279782 - Polymers conjugated with platinum drugs: Various biocompatible polymers having platinum compounds conjugated thereto are prepared. Such polymers are useful for a variety of drug, biomolecule, and imaging agent delivery applications. Also disclosed are methods of using the polymers to treat, diagnose, and/or image a subject.... Agent: Knobbe Martens Olson & Bear LLP

20080279779 - Ct tomographic imaging process and system: A CT radiographic imaging process implements a processing operation on images in order to detect the use of a saline solution. When a saline solution is detected, it extracts a component or a portion of a component that does not appear to be contrasted in the initial images, for example,... Agent: General Electric Company Global Patent Operation

20080279783 - Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production: A method for producing surfactant-stabilized microcapsules or nanocapsules including the steps of (a) preparing a suspension comprising a non-ionic sorbitan detergent and a salt in phosphate buffered saline; (b) adding to the suspension a nonionic polyoxyethylenesorbitan detergent to produce a solution; (c) heating while stirring the solution of step (b)... Agent: Drinker Biddle & Reath LLP

20080279780 - Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer: A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080279784 - Nasal administration of benzodiazepines: Particulate formulations of benzodiazepines, such as diazepam, are used for nasal administration of diazepine drugs to patients. Multimodal particulate formulations of benzodiazepines and methods for their use, e.g. by nasal administration for the treatment of seizure, are also provided.... Agent: Wilson Sonsini Goodrich & Rosati

20080279790 - Azeotrope-like compositions of pentafluoropropane and chloropropane: This invention provides azeotrope-like compositions of 1,1,1,3,3-pentafluoropropane and 2-chloropropane that are environmentally desirable for use as refrigerants, aerosol propellants, metered dose inhalers, blowing agents for polymer foam, heat transfer media, and gaseous dielectrics.... Agent: Honeywell International Inc.

20080279789 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and... Agent: Wilson Sonsini Goodrich & Rosati

20080279787 - Hard surface disinfecting compositions comprising poorly aqueous soluble quaternary ammonium compounds: Disinfecting compositions based on one or more poorly aqueous soluble quaternary ammonium compounds which exhibit reduced corrosion tendencies, one or more nonionic surfactants, optionally one or more further constituents particularly those which enhance the appearance of the compositions, wherein the compositions are largely aqueous in nature and includes little or... Agent: Norris, Mclaughlin & Marcus

20080279786 - Method for extending lifespan delaying the onset of age-related disease: A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention... Agent: Wilson Sonsini Goodrich & Rosati

20080279785 - Novel synthetic agonists of toll-like receptors containing cg dinucleotide modifications: The invention relates to the therapeutic use of oligonucleotides as immune modulatory agents in immunotherapy applications. More particularly, the invention provides immune modulatory oligonucleotide compositions for use in methods for generating an immune response or for treating a patient in need of immune modulation. The immune modulatory oligonucleotides of the... Agent: Keown & Zucchero, LLP

20080279788 - Propellant for dosing aerosols comprising packagings: The invention relates to a pharmaceutical product comprising a dosing aerosol containing a propellant, an effective quantity of adsorbent, a pharmaceutically active substance, substance formulation or substance mixture, and a packaging enclosing the adsorbent and the dosing aerosol with the pharmaceutically active substance, substance formulation or substance mixture.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080279791 - Use of isoeugenol methyl ester as an agent against bad breath: The use of isoeugenol methyl ether is described as an agent (i) to inhibit and/or prevent the growth of and/or to destroy micro-organisms causing bad breath and/or (ii) to combat bad breath.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080279793 - Flavonoids as synergists for enhancing the action of self-tanning substances: The invention relates to the use of at least one flavonoid having an uncharged flavan skeleton as synergist for enhancing the action of self-tanning substances, such as trioses and tetroses, in cosmetic and dermatological formulations and to corresponding novel compositions and to the preparation thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20080279794 - Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin: e

20080279795 - Tertiary amine functional complex polyester polymers and methods of production and use: A polyesteramine comprises at least one tertiary amine group, at least one ester linkage and at least one alkyl chain. It is produced by reacting at least one tertiary amine functional polyol, at least one polyfunctional carboxylic acid and at least one monofunctional carboxylic acid or monofunctional alcohol. The polyesteramine... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20080279796 - Transition metal-containing effect pigments: The present invention relates to effect pigments comprising transition-metal oxides or transition-metal hydroxyoxides or transition-metal hydroxides based on flake-form substrates which are uncoated or coated with one or more metal oxides, and to the use thereof, inter alia in paints, coatings, printing inks, plastics and in particular in cosmetic formulations.... Agent: Millen, White, Zelano & Branigan, P.C.

20080279797 - Cosmetic nanocomposites based on in-situ cross-linked poss materials: A cosmetic composition for caring for and/or making up the skin, lips and/or body in the form of a film, which is non-transferable, long-lasting with a comfortable feeling of use to consumers over long periods of wear time. The composition contains graftable POSS which forms a film when it cures... Agent: Joan M. Mcgillycuddy, Esq. Avon Products Inc.

20080279799 - Amphiphilic co-polymer conjugates for a controlled release of active molecules: The present invention relates to the field of perfumery. More particularly, it concerns polyethylene or polypropylene based polymers that have at least one β-oxy or β-thio carbonyl moiety capable of liberating a perfuming molecule such as, for example, an α,β-unsaturated ketone, aldehyde or carboxylic ester. The present invention concerns also... Agent: Winston & Strawn LLP Patent Department

20080279800 - Aromachemicals: e

20080279798 - Gel-type water absorbent: The invention provides a gel-type water absorbent with rich flexibility and elasticity, with less variation in strength of gel during preservation, with low viscosity of sol, with easy processability, having a physical property with extremely less water discharge, and having functions of water absorbency and water solubility. The gel-type water... Agent: Trexler, Bushnell, Giangiorgi, Blackstone & Marr, Ltd.

20080279801 - Water-in-oil microemulsions for hair treatment: The present invention provides a water-in-oil microemulsion for hair treatment comprising: (a) an oil phase comprising: (i) a first oily component which is one or more glyceride fatty esters, and (ii) a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20... Agent: Unilever Patent Group

20080279804 - Hair styling formulation and method of use: In accordance with the present invention, a highly effective, hair styling foundation composition and a method of use are achieved. By employing the present invention, the hair styling foundation composition enhances the performance and efficacy of additional compositions, such as styling polymers and conditioning treatments, while also creating a protective... Agent: Melvin I. Stoltz

20080279805 - Use of non-film-forming cationic latices for increasing the volume of the hair:

20080279802 - Permanent reshaping of colored fibers containing keratin: A process for improving the color stability of colored fibers containing keratin, in particular human hair, during the permanent shaping of fibers containing keratin, compositions suitable for this purpose comprising at least one silk protein hydrolyzate derivatized with at least one fatty acid and at least one keratin-reducing compound, and... Agent: Paul & Paul

20080279803 - Method and composition for restructuring keratin fibers: The invention relates to a method for restructuring keratin fibers, whereby a keratin fiber is contacted with (a) an aqueous preparation of at least one polysulfide of formula (I), wherein R<3> represents hydroxy or the group (II), R<4> represents hydrogen or the group (III), A is a bond or a... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20080279807 - Biodegradable phosphoester polyamines: Novel biodegradable phosphoester polyamines are disclosed. The biodegradable phosphoester polyamines may be utilized as cross-linkers for sprayable compositions which may be used as tissue adhesives or sealants.... Agent: Tyco Healthcare Group Lp

20080279806 - Dermal filler composition: Disclosed herein is a dermal filler composition. The composition includes polymethylmethacrylate (PMMA), cross-linked dextran, hydroxypropyl methylcellulose (HPMC), and physiological saline or distilled water. The composition rapidly restores volume at application sites by injection, does not require pre-testing, such as allergic skin testing, because it does not cause severe allergic reactions,... Agent: Birch Stewart Kolasch & Birch

20080279808 - 2,3,4,5-tetrahydroxy-6-sulfooxy hexanoic acid, pharmaceutically acceptable salts and equilibrium forms thereof, processes for their preparation, pharmaceutical compositions comprising such compounds and their medical use: The invention relates to novel compounds of general formula I wherein M represents hydrogen, or a metallic cation, preferably an alkaline metal, or alkaline-earth metal, and n is equal to 1, 2 or 3. The present invention also comprises compounds of general formula I in their equilibrium forms, including lactonic... Agent: Sughrue Mion, PLLC

20080279809 - Coating material for metal surfaces having antiadhesive properties: A composition curable by polymerization, as well as a process of applying the composition and metal substrates coated therewith, the composition comprising: a) at least one metal compound which reacts before and/or during the curing of the composition by polymerization, with at least one of components b), c) or, if... Agent: Henkel Corporation

20080279811 - Animal attractant and associated dispenser: A dispenser for an animal attractant including: a housing, wherein the housing includes a chamber for containing a spool; a spool, wherein the spool is associated with the chamber of the housing, and wherein the spool is associated with a deer attractant; and wherein the deer attractant includes a substrate,... Agent: King & Partners, PLC

20080279810 - Pheromones: The apple leaf midge and raspberry cane midge pheromones have been found to be acetoxyheptadecenone and acetoxyundecanone, respectively, and uses for these and related compounds are provided, including monitoring population levels of the midge and control of midge populations by disrupting mating patterns.... Agent: Foley & Lardner LLP

20080279813 - Cd4+ cd25+ t-cells activated to a specific antigen: The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of... Agent: Myers Bigel Sibley & Sajovec

20080279818 - Combination preparation of a biological response modifier and an anticancer agent and uses thereof: The present invention provides anticancer biological response modifier combinations. In accordance with an aspect of the present invention, there is provided a combination comprising: (i) a composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: is extracted from bile of animals; is capable... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080279812 - Disease prevention and vaccination prior to thymic reactivation: The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient by disrupting sex steroid signalling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic... Agent: Wilmerhale/boston

20080279816 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20080279815 - Method for developing testing, and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates: This invention describes the principles and procedures suitable for developing, testing, manufacturing, and using combinations of various amphipatic, if necessary modified, macromolecules (such as polypeptides, proteins, etc.) or other chain molecules (such as suitable, e.g. partly hydrophobised, polynucleotides or polysaccharides) with the aggregates which comprise a mixture of polar and/or... Agent: Wilson Sonsini Goodrich & Rosati

20080279814 - Methods of treating neurological conditions with hematopoeitic growth factors: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080279817 - Treatment of autoimmune diseases and allograft rejection with il-21: The invention provides combination treatments with IL-21, an analogue, a derivative or active fragment thereof, an IL-21 mimetic or IL-21 polynucleotide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080279821 - Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080279819 - Combinations therapy for treatment of demyelinating conditions: The present invention provides novel methods and compositions for the treatment and prevention of demyelinating conditions. One demyelinating condition treated by the methods and compositions of the invention is multiple sclerosis. Also treated are symptoms associated with multiple sclerosis.... Agent: Adamas Pharmaceuticals, Inc.

20080279820 - Compositions and methods for treating burns: The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof, and a pharmaceutically acceptable excipient.... Agent: The Law Offices Of Andrew D. Fortney, Ph.d., P.C.

20080279822 - Crystalline polymorphs of a cxc-chemokine receptor ligand: These four polymorphic forms, herein referred to as Forms I, II III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080279823 - Recombinant interferon 2alpha (infalpha2) mutants: The present invention provides IFNα2 mutants and active fragments, analogs, derivatives, and variants thereof that have improved specific agonist or antagonist activity as compared to wild-type IFNα2. The present invention further provides pharmaceutical compositions comprising IFNα2 mutants useful for treating or preventing cancer, autoimmune diseases, infectious diseases or disorders associated... Agent: Winston & Strawn LLP Patent Department

20080279824 - Articles for tissue regeneration with biodegradable polymer: The invention is to articles made from extracellular matrix sheets that encase biodegradable polymeric material. Methods of healing wounds or regenerating tissue at sites of defect by placing said articles in mammals are claimed. The biodegradable polymer can change quality upon contact with a physiological parameter such as temperature or... Agent: Leigh Hunt Firestone

20080279831 - Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer: The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response,... Agent: Jones Day

20080279832 - Osteogenic differentiation of preosteoblastic cells: The application discloses a method for making bone at a bone defect site which includes generating a member of a transforming growth factor superfamily of proteins; generating a population of cultured connective tissue cells that may contain a vector encoding a gene, or a population of cultured connective tissue cells... Agent: Jhk Law

20080279825 - Cartilage material: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or... Agent: Leydig Voit & Mayer, Ltd

20080279826 - Method for expanding cd4+ cd25+ t regulator cells: A method for generating/expanding in vitro a CD4+CD25+ T regulatory (Tr) cell and the use thereof in the treatment of diseases associated with a cell-mediated immune response (including T- and antibody-mediated responses).... Agent: Marshall, Gerstein & Borun LLP

20080279828 - Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby: Ex vivo and in vivo methods of expanding a population of stem and/or progenitor cells, while at the same time reversibly inhibiting differentiation of the stem and/or progenitor cells by providing the stem and/or progenitor cells with an effective amount of at least one copper chelate, so as to maintain... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080279829 - Phenyl-(4-phenyl-pyrimidin-2-yl)-amines for enhancing immunotolerance: The use of a phenyl-(4-phenyl-pyrimidin-2-yl)-amine for the preparation of a medicament for enhancing immunotolerance in a mammal; and uses, methods, processes and pharmaceutical combinations and compositions comprising such phenyl-(4-phenyl-pyrimidin-2-yl)-amine.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080279827 - Preparation and xenotransplantation of porcine islets: e

20080279830 - Spongy epithelial cell scaffold for vascularizing wounds: The present invention provides isolated apoptotic epithelial scaffolds. The scaffolds find use in promoting re-vascularization of wounded tissues. The present invention also provides isolated or ex vivo tri-layered cell sorted tissues comprised of a bottom layer comprised of an apoptotic epithelial scaffold, a middle layer comprised of mesenchymal cells, and... Agent: Townsend And Townsend And Crew, LLP

20080279833 - Laminate sheet articles for tissue regeneration: The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further... Agent: Leigh Hunt Firestone

20080279836 - Method of making a cell therapy formulation: Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation signals upon cross-linking and mixing the labeled cells with biodegradable... Agent: Westman Champlin & Kelly, P.A.

20080279835 - Method of stem cell therapy for cardiovascular repair: A method of treating acute myocardial infarction has the steps of providing human umbilical cord blood cells (HUCBC); and administering the HUCBC to the individual with the acute myocardial infarction at particular time intervals after said myocardial infarction. Preferably the intervals are about one to about three hours or about... Agent: Smith Hopen, Pa

20080279834 - Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals: An affinity ligand is reactive to the GARP protein may be capable of binding to an extracellular domain of GARP protein expressed on regulatory T (Treg) cells. The affinity ligand may be an antibody and may be used to identify Treg cells. A method comprises providing a blood sample from... Agent: Hahn Loeser & Parks, LLP

20080279837 - Composition for maintaining androgen and androgen-like uptake potential by cells: A composition comprising at least a therapeutically effective amount of L-carnitine fumarate, and an extract of Coleus forskohlii is provided to maintain androgen and androgen-like uptake potential in cells, via simultaneous increase in the availability of androgen receptors and improved availability of androgen and androgen-like molecules. A method of same... Agent: Torys LLP

20080279838 - Reconstructed human mariner transposon capable of stable gene transfer into chromosomes in vertebrates: The present invention refers to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using a member of the human mariner transposases. The invention further refers to this transposase and to transposons used in the inventive gene transfer system, comprising a nucleic acid... Agent: Klauber & Jackson

20080279839 - Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency: The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and/or lactase. Furthermore, the invention discloses methods for treating pancreatic... Agent: Hunton & Williams LLP Intellectual Property Department

20080279840 - Histaminase of vegetable origin for use in the treatment of allergic and septic shock and of allergic asthma: A histaminase of vegetable origin to be used in the treatment of allergic and septic shock and in allergic asthma, and the preparation of the histaminase for pharmaceutical use and the corresponding pharmaceutical compositions.... Agent: Paul D. Greeley Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20080279842 - Controlled release dressing for enzymatic debridement of necrotic and non-viable tissue in a wound: A dressing for debridement of necrotic and non-viable tissue in a wound, wherein the dressing comprises an effective amount of one or more proteolytic enzymes incorporated in a degradable polymeric material. The dressing of the invention provides effective debridement of necrotic wounds over a prolonged period of time, as the... Agent: Jacobson Holman PLLC

20080279841 - Novel therapeutic molecular variants and uses thereof: The present invention relates generally to a sphingosine kinase variant and to derivatives, analogues, chemical equivalents and mimetics thereof exhibiting reduced catalytic activity and, more particularly, to sphingosine kinase variants which exhibit a reduced capacity to phosphorylate sphingosine to sphingosine-1-phosphate. The present invention also contemplates genetic sequences encoding said sphingosine... Agent: Morrison & Foerster LLP

20080279843 - Method for improving insulin sensitivity by administering an inhibitor of antitrypsin: Methods of delaying the onset or treating the progression of Type 2 diabetes in subjects that have increased blood levels of an inflammation marker protein. In one embodiment, the method includes administering an inhibitor OF α1-antitrypsin (AT) to the subject, and optionally co-administering an anti-diabetic medicament or anti-inflammatory agent to... Agent: Faegre & Benson LLP Patent Docketing

20080279792 - Cosmetic and dermatological self-tanning formulations comprising dihydroxyacetone and glycerin: Cosmetic or dermatological self-tanning preparations which contain dihydroxyacetone and are characterized in that they also contain more than 5 percent by weight (relative to the total weight of the preparation) of glycerin, and the use thereof.... Agent: Greenblum & Bernstein, P.L.C

20080279845 - Combination therapy with a compound acting as a platelet adp receptor inhibitor: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.... Agent: Foley & Lardner LLP

20080279844 - Methods for treating cancer targeting transglutaminase: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one... Agent: Baker Botts, LLP

20080279846 - Methods of treatment and prevention of neurodegenerative diseases and disorders: The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB,... Agent: David S. Resnick

20080279851 - Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated... Agent: Medimmune, LLC Jonathan Klein-evans

20080279850 - B-cell reduction using cd37-specific and cd20-specific binding molecules: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further... Agent: Marshall, Gerstein & Borun LLP

20080279847 - Humanized anti-tag-72 monoclonal antibodies: The present invention relates to humanized antibodies specific to a tumor associated glycoprotein, TAG-72, and anticancer compositions comprising the humanized antibodies. In detail, the present invention relates to a humanized antibody which has enhanced antigen binding affinity by mutating a heavy chain of a humanized antibody PXA/HzK specific for TAG-72,... Agent: Casimir Jones, S.c.

20080279849 - Lymphoid chemokines in the diagnosis, monitoring and treatment of inflammatory disease: Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells... Agent: Fish & Richardson P.C.

20080279848 - Methods of treating lupus using cd4 antibodies: Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody... Agent: Quine Intellectual Property Law Group, P.C.

20080279852 - Methods of treatment with glycosylated antibodies: t

20080279854 - Polypeptide: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.... Agent: Marshall, Gerstein & Borun LLP

20080279853 - Treatment of cancer: Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080279855 - Dna replication modulating peptides, nucleic acids encoding them, and their use in pharmaceutical compositions: The present invention relates to the use of a peptidic sequence which comprises or is constituted of a peptidic chain of at least contiguous amino acids selected from the amino acid sequence SEQ ID NO: 4, SEQ ID NO: 4 being delimited by the amino acid in position 76 and... Agent: Young & Thompson

20080279856 - Inhibition of bradykinin release: The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces a HBP which binds to a HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising... Agent: Reza Green

20080279857 - Therapeutic agent: The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure... Agent: Speckman Law Group PLLC

20080279859 - Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for... Agent: Paul D. Yasger Abbott Laboratories

20080279858 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080279860 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20080279861 - Method for stimulating a host immune system by administering an allogeneic cell material: A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy... Agent: Westman Champlin & Kelly, P.A.

20080279862 - Combination therapy with co-stimulatory factors: Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080279863 - Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases: The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to... Agent: Alston & Bird LLP

20080279864 - High throughput screen utilizing newly discovered intramolecular neuronal calcium channel interactions to discover new analgesics: The present invention relates to compositions to treat CaV2 disorders. The invention also relates to methods treating CaV2 disorders. The invention further relates to kits for treating CaV2 disorders in a subject. The invention further relates to methods of identifying novel treatments for treating Cav2 disorders in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20080279865 - Therapy of prostate cancer with ctla-4 antibodies and hormonal therapy: The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody, or an antigen-binding portion thereof, particularly a human antibody to human CTLA4, e.g., antibody 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also known as 11.2.1), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also known as... Agent: Pfizer Inc

20080279867 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals Inc.

20080279866 - Induction of immunosuppression by inhibition of atm: The present invention is directed to methods of inducing immunosuppression in a patient by administering an inhibitor of the enzyme Ataxia telangiectasia mutated (Atm). The method may be used as a treatment for allergies, autoimmune diseases or lymphomas. It may also be used to prevent organ rejection in transplant patients... Agent: Law Office Of Michael A. Sanzo, LLC

20080279868 - Antibody-drug conjugates and methods of use: The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.... Agent: Medarex C/o Darby & Darby P.C.

20080279870 - Alk protein tyrosine kinase, cells and methods embodying and using same: The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated development of a T cell lymphoproliferative disorder or B cell plasma cell tumor, together with the identification of cells transduced with the ALK... Agent: Klauber & Jackson

20080279869 - Method for reducing neuronal degeneration by administering cns-derived peptides or activated t cells: Compositions are provided for promoting nerve regeneration or reducing or inhibiting degeneration in the CNS or PNS to ameliorate the effects of injury or disease. The composition includes an active ingredient selected from:(a) a peptide obtained by modification of a self-peptide derived from a CNS-specific antigen, which modification consists in... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080279873 - Active immunization to generate antibodies to soluble a-beta: The invention provides methods useful for effecting prophylaxis or treatment of Alzheimer's disease. Such methods entail administering A-beta fragments from a central or C-terminal regions of A-beta. Such fragments can induce a polyclonal mixture of antibodies that specifically bind to soluble A-beta without binding to plaques. The antibodies can inhibit... Agent: Townsend And Townsend And Crew, LLP

20080279874 - Compositions and methods for modulation of plk1 kinase activity: Described are compositions and methods for activating a Plk1 protein as well as phospho-specific anti-Myt1 antibodies that can be used to detect phosphorylation of Myt1. Activated Plk1 protein, phospho-specific anti-Myt1 antibodies, and/or Plk1 substrates can be used in screening assays to identify compounds that modulate the ability of Plk1 to... Agent: Wyeth Patent Law Group

20080279871 - Immunogenic composition: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and... Agent: Townsend And Townsend And Crew LLP

20080279872 - Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme: The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.... Agent: Benjamin Aaron Adler, Ph.d., J.d. Adler & Associates

20080279875 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080279876 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080279878 - Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The... Agent: Fennemore Craig

20080279877 - Hpv antigens, vaccine compositions, and related methods: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by human papilloma virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.... Agent: Choate, Hall & Stewart LLP

20080279879 - Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope: Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080279880 - Peptide vaccines against group a streptococci: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can... Agent: Klarquist Sparkman, LLP

20080279881 - Truncated recombinant major outer membrane protein antigen (r56) of orientia tsutsugamushi strains karp, kato and gilliam and its use in antibody based detection assays and vaccines: A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, Orientia tsutsugamushi for the Karp, Kato and Gilliam strains has been produced. The invention is useful for detecting prior exposure to scrub typhus, screening for and/or identification of at least one infectious... Agent: Naval Medical Research Center Attn: (code 00l)

20080279882 - Phyto-nutraceutical synergistic composition for hyperlipedemic condition: A Phytoceutical composition for the prevention and treatment of hyperlipidemia—cholesterol and triglyceride disorder—is provided. A specific combination of extracts of plants and nutraceuticals is taught, as well as principles for varying the formulations based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization and selecting... Agent: Jose Olalde Rangel

20080279883 - Ingestible malodor eliminator for animals: An ingestible formulation for a malodor eliminator for animals that works systemically and comprises a formulation of a chlorophyll derivative combined with Spirulina and alfalfa wherein the chlorophyll derivative is at least 90 percent of the formulation is presented. In the preferred embodiment, the chlorophyll derivative is chlorophyllin. The formulation... Agent: Law Offices Of Mark E. Wiemelt, P.C.

20080279884 - Ingestible plaque eliminator for animals: An ingestible formulation for a plaque eliminator for animals that works systemically and comprises a formulation of a chlorophyll or a chlorophyll derivative combined with Spirulina and alfalfa wherein the chlorophyll derivative is at least 90 percent of the formulation is presented. In the preferred embodiment, the chlorophyll derivative is... Agent: Robert L. Knechtel Law Offices Of Mark E. Wiemelt, P.C.

20080279885 - Topical formulation containing latex of fraction thereof, and cosmetic treatment method: The present invention refers to a topical formulation containing natural latex or fraction thereof, for topical application, aiming to provide skin regeneration. It particularly refers to a formulation comprising latex from plants of the families Euphorbiaceae, such as Hevea brasiliensis, Apocinaceae, such as guava and sorb, Compositae such as guayule,... Agent: Fitch Even Tabin And Flannery

20080279887 - Method of enhancing a targeted immune response against tumors: The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose... Agent: Leydig, Voit & Mayer, Ltd.

20080279886 - Safer attenuated virus vaccines with missing or diminished latency of infection: Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus.... Agent: National Institutes Of Health

20080279888 - Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof: The present invention provides genetically engineered cell lines, recombinant vectors, and vaccines. The present invention also provides methods for generating an in vitro system for Varicella zoster virus (VZV), and the in vitro systems generated by these methods. The present invention further provides methods for reactivating VZV, and VZV reactivated... Agent: Wilmerhale/columbia University

20080279889 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080279890 - Viral antigens: The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080279892 - Recombinant rsv virus expression systems and vaccines: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2,... Agent: Medimmune, LLC Jonathan Klein-evans

20080279891 - Viral adjuvants: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or... Agent: Myers Bigel Sibley & Sajovec

20080279894 - Bacterial glycolipid activation of cd1d-restricted nkt cells: Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting... Agent: Michael Best & Friedrich LLP

20080279893 - Lawsonia intracellularis immunological proteins: The present invention provides nucleic acid and amino acid sequences useful as the immunogenic portion of vaccines or immunogenic compositions effective for lessening the severity of the clinical symptoms associated with Lawsonia intracellularis infection or conferring protective immunity to an animal susceptible to such infection. Preferred amino acid sequences are... Agent: Tracey S. Truitt Erickson & Kleypas, L.L.C.

20080279895 - Targeted delivery of botulinum toxin to the sphenopalatine ganglion: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.... Agent: Allergan, Inc.

20080279896 - Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy: The present invention relates to a method of treating a movement disorder in a patient, the method comprising administering a medicament comprising an effective amount of chemodenervating agent to the patient, wherein the patient is subjected to a muscle stimulation therapy, for example an movement therapy or an muscle activation... Agent: The Firm Of Hueschen And Sage

20080279897 - Method of treating cellular damage: The present invention relates generally to a method of modulating hyperglycaemia-induced endothelial cell functioning and agents useful for same. More particularly, the present invention relates to a method of modulating hyperglycaemia-induced vascular endothelial cell functioning by modulating intracellular sphingosine kinase-mediated signalling. The method of the present invention is useful, inter... Agent: Scully, Scott, Murphy & Presser, P.C.

20080279898 - Biologically degradable compositions for medical applications: A medical article is disclosed, comprising a biologically degradable AB block copolymer and a biologically degradable polymer that is capable, at equilibrium and at room temperature, of absorbing less than about 5 mass % water.... Agent: Squire, Sanders & Dempsey LLP

20080279901 - Composition comprising encapsulated silicone compounds: The present invention relates to a cosmetic composition intended for the care and/or make-up of keratinous substance(s) comprising, in a physiologically acceptable medium, at least one compound X, one compound Y and at least one catalyst, with at least one of the compounds X or Y being a polyorganosiloxane, and... Agent: Oliff & Berridge, PLC

20080279899 - Cosmetic composition in powdered form: The subject of the present invention is an anhydrous cosmetic composition in powdered form comprising at least one pulverulent phase and a fatty binder, the said pulverulent phase comprising i) 30 to 70% by weight, relative to the total weight of the composition, of at least one pigment, and ii)... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080279902 - Delivery system and method to deliver homeopathic complexes comprising homeopathic colored pigment products for cosmetic use: The present invention provides a delivery system and method to deliver topically homeopathic amounts of at least one Homeopathic Complex. It further provides a Homeopathic Colored Pigment Product containing a coloring agent having a plurality of particles having at least one surface and a homeopathically effective amount of at least... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20080279903 - Edible thin film strips and process for making: A method to produce edible film and apply the method to produce products containing ingredients from natural sources in one film.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080279900 - Gel useful for the delivery of cosmetic active ingredients: A gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles is described.... Agent: Lucas & Mercanti, LLP

20080279904 - Ph-regulated polyamide powder for cosmetic applications: The present invention relates to polyamide powders suitable for cosmetic applications are described which have a pH of 4.0 to 7.0, cosmetic compositions containing the polyamide powders and processes of making the same.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080279905 - Fabric and clothes for atopic dermatitis patients: To provide a fabric and clothing having a low irritation to patients with atopic dermatitis with high productivity. The fabric is produced as a fabric for patients with atopic dermatitis, which is contactable with an affected area of patients with atopic dermatitis and comprises an ethylene-vinyl alcohol (EVOH)-series fiber comprising... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080279907 - Antimicrobial medical devices and methods for making and using same: In general, this application is directed to medical devices that exhibit antimicrobial activity and to methods for preparing and using the medical devices. The medical devices of the present application include a polymeric portion that has been impregnated with a paraben and an organic dye in a manner whereby the... Agent: Krieg Devault LLP

20080279906 - Treatment of amyotrophic lateral schlerosis: The present invention relates to the treatment of motoneuron diseases. More particularly the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a preclinical ALS animal model induces a significant motor performance and... Agent: Trask Britt

20080279910 - Composite hemocompatible material and method for its production: According to the invention, the hemocompatible material comprises a strong and leaklight synthetic substrate, to which a biological tissue adheres by virtue of the constituent substance of said substrate dispersing in a solvent.... Agent: Stevens Davis LLP

20080279908 - Hydroxyapatite-binding peptides for bone growth and inhibition: Hydroxyapatite (HA)-binding peptides are selected using combinatorial phage library display. Pseudo-repetitive consensus amino acid sequences possessing periodic hydroxyl side chains in every two or three amino acid sequences are obtained. These sequences resemble the (Gly-Pro-Hyp)x repeat of human type I collagen, a major component of extracellular matrices of natural bone.... Agent: Lawrence Berkeley National Laboratory

20080279909 - Immobilized biologically active entities having a high degree of biological activity following sterilization: The present invention relates to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.... Agent: Gore Enterprise Holdings, Inc.

20080279911 - Medical devices having crosslinked polymeric surfaces: According to an aspect of the invention, medical devices are provided which contain at least one polymeric region. The polymeric region contains at least one copolymer, which includes at least one high Tg vinyl aromatic monomer and at least one low Tg monomer. Moreover, the polymeric region contains at least... Agent: Mayer & Williams PC

20080279912 - Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders: The invention provides methods for alleviating eye disorders due to increased intraocular pressure (“IOP”) or inflammation by administering to the eye or eyes of an individual in need thereof a cis-epoxyeicosatrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. The invention further provides for reducing IOP or inflammation... Agent: Townsend And Townsend And Crew, LLP

20080279913 - Use of salicylaldehyde isonicotinoyl hydrazone (sih) for protection against retinal disease: This invention relates to methods for treating age-related macular degeneration, blindness or glaucoma using an iron-chelator SIH.... Agent: Pearl Cohen Zedek Latzer, LLP

20080279914 - Transdermal composition comprising piroxicam-inorganic material complex and patch system comprising the same: There is disclosed a transdermal composition comprising from about 0.1 to 25% by weight of a piroxicam-inorganic material complex composed of a swellable clay and piroxicam intercalated between layers thereof, from about 50 to 80% by weight of an adhesive polymeric material, and from about 0.1 to 25% by weight... Agent: Gibbons P.C.

20080279915 - Matrix-controlled transdermal therapeutic system based on an adhesive for administering norelgestromin or the combination thereof with an estrogen: The invention relates to a transdermal therapeutic system comprising an active-ingredient-impermeable top layer, an active-ingredient-containing matrix and a removable protective layer, the matrix comprising or consisting of norelgestromin and an optional oestrogen as active ingredients as well as also a pressure-sensitive hot-melt adhesive and optional auxiliaries.... Agent: Edwards Angell Palmer & Dodge LLP

20080279917 - Bisbenzamidines for the treatment of pneumonia: A method of combating infectious agents, such as Pneumocystis pneumonia, and a method of treating a subject in need of such treatment is disclosed. The method comprises administering to the subject a bis-benzamidoxime of formula (I) wherein the linker is a di-substituted cyclic moiety of any ring size and may... Agent: Frost Brown Todd, LLC

20080279920 - Compositions for treating respiratory viral infections and their use: The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the... Agent: The Law Office 0f Geoffrey M. Karny

20080279921 - Gel-formulations of hydrophobic photosensitizers for mucosal applications: The present invention relates to improved methods of formulations of hydrophobic photosensitizers, and their precursors, for mucosal administration. The formulation of the invention comprises of hydrophobic photosensitizers which have been incorporated into suitably sized liposomes. Additionally, these formulations include the incorporation of PS-loaded liposomes into a copolymer matrix. The liposome... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20080279924 - Hla class i a2 tumor associated antigen peptides and vaccine compositions: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080279918 - Liposome and method for injecting substance to cell using this liposome: It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a... Agent: Sughrue Mion, PLLC

20080279916 - Liposome preparation: A liposome preparation is provided. This liposome preparation is capable of stably encapsulating a drug which is unstable under an acidic condition, and such stable encapsulation is realized without detracting the effect realized by the modification of the membrane by a hydrophilic macromolecule such as stability in blood. More specifically,... Agent: Buchanan, Ingersoll & Rooney PC

20080279919 - Liposomes for protection against toxic compounds: Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds,... Agent: Timothy S. Corder Vinson & Elkins

20080279925 - Method(s) of preventing, arresting, reversing and treatment of atherosclerosis: A method of preventing, arresting, reversing and treatment of atherosclerosis by enhancing the activities of Δ6 and Δ5 desaturases such that the cell, tissue, and plasma levels of various polyunsaturated fatty acids (PUFAs) and, in particular that of endothelial cells lining the blood vessels will increase. More particularly, the invention... Agent: Undurti Narasimha Das

20080279927 - Non-pegylated long-circulating liposomes: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080279922 - Releasable linkage and compositions containing same: A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in... Agent: Robins & Pasternak LLP

20080279923 - Use of microtubule stabilizing compounds for the treatment of lesions of cns axons: The present invention provides a use of one or more microtubule stabilizing compounds for the preparation of a pharmaceutical composition for the treatment of lesions of CNS axons wherein the pharmaceutical composition is administered locally directly into the lesion or immediately adjacent thereto, whereby the one or more compound(s) is/are... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080279926 - Vaccine compositions comprising a saponin adjuvant: An immunogenic composition in a dose volume suitable for human use comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080279928 - Method for producing ultrafine submicronic suspensions: The invention concerns a method for producing ultrafine suspensions, characterized in that a substance in the form of a solid product at 20° C. is dissolved in a solvent, in that the solvent is very rapidly substantially drawn from said solution, in that the powder thus obtained, whereof the particles... Agent: Manelli Denison & Selter

20080279930 - Controlled-release flupirtine compositions, compacts, kits and methods of making and use thereof: The present invention relates to compositions and compacts comprising flupirtine or a pharmaceutically acceptable salt thereof in which there is controlled-release of at least a portion of flupirtine or a pharmaceutically acceptable salt thereof. The invention further relates to kits comprising such compositions and compacts, and methods of making and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080279929 - Nanoparticulate and controlled release compositions comprising cefditoren: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug,... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20080279931 - Composition for treatment of pain: The present invention is a composition delivering effective amounts of Glucosamine, Devils Claw, SAM, and NSAID in a single dosage unit.... Agent: Robert M. Schwartz, P.A.

20080279932 - Compounds: The present invention relates to novel salt forms of vildagliptin (LAF237), i.e. salt forms of(S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine.... Agent: Novartis Corporate Intellectual Property

20080279933 - Flurbiprofen and muscle relaxant combinations: This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an α-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.... Agent: Arent Fox LLP

20080279934 - Extended release formulation for pralnacasan: This invention relates to a sustained release tablet comprising at least two layers, wherein at least one layer rapidly releases pralnacasan and the other layer releases pralnacasan in a delayed manner. This tablet is particularly suitable for the treatment of a condition such as autoimmune diseases, type I and type... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080279935 - Composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base: The invention relates to a composition being substantially free from water comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids (PUFA), wherein said PUPA content of said powder is from about 5 to about 50% (w/w), said powder being homogenously distributed in an effervescent base, wherein said effervescent base... Agent: Merchant & Gould PC

20080279936 - Estradiol metabolites for reduction of endothelin production: Methods are provided for the decrease of endothelin production in an individual. In particular, the methods include the reduction of endothelin production by the administration of a composition comprising an estradiol metabolite. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol or prod rugs thereof. The composition may be in... Agent: The Mccallum Law Firm, P. C.

20080279937 - Controlled release potassium chloride tablets: A unit dosage form, such as a tablet for delivering potassium into the body in a controlled release fashion, comprises of a multiplicity of microencapsulated potassium chloride crystals, which are further coated with a plasticized polymer to improve compressibility of the microcapsules. The compressible microcapsules are blended with a compression... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080279938 - Zaltoprofen-containing sustained release tablet and process for the preparation thereof: Disclosed is a zaltoprofen-containing sustained release tablet comprising granules containing zaltoprofen and a binder, in which the granules are dispersed in a matrix comprising a hydrophilic polymer, and a diluent is present either in the granules or in the matrix.... Agent: Knobbe Martens Olson & Bear LLP

20080279939 - Extracellular matrix compositions for tissue regeneration: The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.... Agent: Leigh Hunt Firestone

20080279941 - Method of treating joints with hydrogel implants: Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of... Agent: Knobbe Martens Olson & Bear LLP

20080279940 - Microemulsions of cannabinoid receptor binding compounds: The present invention relates to a novel spontaneously dispersible pharmaceutical composition, e.g. a microemulsion preconcentrate, in which the active drug substance is a cannabinoid receptor binding compound, in particular a corresponding naphthalene derivative, that is useful, e.g., for the treatment or prevention of chronic pain.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080279944 - Composite hydrogel drug delivery systems: Compositions and methods are provided to control the release of relatively low molecular weight therapeutic species through hydrogels by first dispersing or dissolving such therapeutic species within relatively hydrophobic rate modifying agents to form a mixture. The mixture is formed into microparticles that are dispersed within bioabsorbable hydrogels, so as... Agent: Dardi & Associates, PLLC

20080279943 - Method of making hydrogel implants: Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of... Agent: Knobbe Martens Olson & Bear LLP

20080279942 - Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker: A pharmaceutical preparation comprising an angiotensin II receptor antagonist, a calcium channel blocker and at least one substance selected from the group consisting of a hydrophilic polymer, an acidic substance and a fluidizing agent. The pharmaceutical preparation has improved dissolution properties.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080279945 - Gel-based delivery of recombinant adeno-associated virus vectors: Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of... Agent: Haynes And Boone, LLP

20080279947 - Menthol-containing solids composition: s

20080279946 - Methods and compositions for increasing infrared absorptivity of a target: Disclosed herein are compositions and methods for increasing the infrared absorptivity of a therapeutic target. Also disclosed are methods for detecting or ablating a therapeutic target that include providing a nanoparticle composition for increasing the infrared absorptivity of the therapeutic target. Subsequently, the therapeutic target having increased infrared absorptivity is... Agent: Wilson Sonsini Goodrich & Rosati

20080279950 - Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof: Provided are nanoparticles prepared by the aggregation of cucurbituril derivatives and having a particle size of 1 to 1,000 nm, a pharmaceutical composition in which a pharmaceutically active substance is loaded into the nanoparticles, and preparation methods thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080279949 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080279948 - Treatment of asthma and copd using triple-combination therapy: in free or salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification; (B) a glycopyrronium salt; and (C) mometasone furoate; for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways... Agent: Novartis Corporate Intellectual Property

20080279952 - Controlled-release flupirtine compositions, compacts, kits and methods of making and use thereof: The present invention relates to compositions and compacts comprising flupirtine or a pharmaceutically acceptable salt thereof in which there is controlled-release of at least a portion of flupirtine or a pharmaceutically acceptable salt thereof. The invention further relates to kits comprising such compositions and compacts, and methods of making and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080279953 - Methods of producing stable pancreatic enzyme compositions: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080279951 - Stable oral benzimidazole compositions prepared by non-aqueous layering process: The present invention relates to processes for the preparation of stable oral compositions of benzimidazole compounds prepared using a non-aqueous layering process.... Agent: Ranbaxy Inc.

20080279954 - Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network: A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is... Agent: Ropes & Gray LLP

20080279955 - Pharmaceutical microparticles: Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins... Agent: Novartis Corporate Intellectual Property

20080279956 - Method for collecting a live placenta cord stem cell: The present invention discloses a method for collecting a live placenta cord stem cell, in which the live placenta cord stem cells are required to be healthy and plenty of endocrine. The cord is first picked with a proper length, then dipped in the sodium citrate solution of a specific... Agent: Rosenberg, Klein & Lee

20080279957 - Immunomodulating compositions from bile: The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: a) is extractable from bile of animals; b) is capable of stimulating monocytes and macrophages in vitro; c) is capable of modulating tumor... Agent: Gary M. Nath Nath & Associates PLLC

20080279958 - Snake venom compositions and methods of use: The invention relates to the discovery that formulations of Lachesis venom decrease circulating TNF-α levels in mammals including humans, and that administration of Lachesis venom-containing formulations to mammals suffering from sepsis, parasitic infection, cisplatin nephrotoxicity, rheumatoid arthritis, cancer and AIDS mitigates symptoms associated with these conditions.... Agent: Akerman Senterfitt

20080279959 - Antimicrobial credit cards, identification cards, membership cards and identification badges and badge holders: A system, method and apparatus provices an antimicrobial card, badge holder or token made from an antimicrobial polymereric material. The antimicrobial polymereric material includes one or more polymers and one or more antimicrobial agents that affect the growth of bacteria, fungi, virus or a combination thereof.... Agent: Chalker Flores, LLP

20080279960 - Silver-containing antimicrobial articles and methods of manufacture: A silver composition comprising silver sulfate, methods of making antimicrobial articles, particularly packaged antimicrobial articles, methods of whitening antimicrobial articles, and packaged antimicrobial articles.... Agent: 3m Innovative Properties Company

20080279961 - Telomere targeting agents as stem cells directed treatments: It is demonstrated in the present invention that G-quadruplex ligands can be used to both shorten telomeres and inhibit telomerase by causing telomere uncapping. The invention relates to compositions and methods of treating cancer stem cells comprising the administration of G-quadruplex ligands, such as 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4), which can effectively... Agent: Fulbright & Jaworski, LLP

20080279962 - Method of scintigraphy: The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for... Agent: Novartis Corporate Intellectual Property

20080279964 - Biofouling control: A system and method for stabilizing bromine in an industrial water system by monitoring and flexible dosing of chlorine oxidant and halide ion stabilizer residual levels. The system comprises chlorine oxidant, and a halide ion source with a halogen stabilizer.... Agent: Andrea C. Walsh Patent And Licensing Department

20080279963 - Physiologically balanced, ionized, acidic solution and methodology for use in wound healing: Described herein is a physiologically-balanced, acidic solution. Typically the solution is prepared by a chemical reactions or by the electrolysis of a solution comprising a mixture of an inorganic salt to form a physiologically balanced solution. This invention also relates to methods for use of the solutions, including a specialized... Agent: Heller Ehrman LLP

20080279965 - Treatment of injury to the brain by inhibition of acid sensing ion channels: Methods and compositions that inhibit acid sensing ion channels are provided for the prevention and treatment of brain injury, including injury caused by stroke or seizure. The methods and compositions of the invention are additionally effective for the reduction of acidosis in the brain.... Agent: Black Lowe & Graham PLLC

20080279966 - Branched-chain amino acid composition for improving skeletal muscle protein metabolism: The present invention relates to compositions and methods for improving skeletal muscle protein metabolism through encouraging skeletal muscle protein synthesis, reducing skeletal muscle protein degradation, and attenuating inflammatory signaling in exercising muscle.... Agent: Torys LLP

20080279967 - Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid: A dietary supplement comprising at least an effective amount of Cissus quadrangularis extract and an effective amount of γ-butyrobetaine. The ingredients of the present dietary supplement act substantially to facilitate a more favorable blood lipid profile, and increase the catabolism of free fatty acids via the phosphorylation of perilipins. In... Agent: Torys LLP

20080279968 - Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids: A nutritional supplement comprising at least a therapeutically effective amount of green tea extract and a therapeutically effective amount of γ-butyrobetaine is provided by the present invention. The ingredients of the present nutritional supplement act substantially simultaneously to induce lipolysis, resulting in free fatty acid release, and increase the catabolism... Agent: Torys LLP

20080279969 - Composition comprising bamboo extract for androgen agonist: The present invention relates to a use of bamboo or bamboo extract to prevent or treat symptoms related to decrease of androgen; a composition for androgen agonist comprising bamboo or bamboo extract; a method for preventing or treating symptoms related to decrease of androgen by administering composition for androgen agonist;... Agent: Fitzpatrick Cella Harper & Scinto

20080279970 - Pharmaceutical composition for treating parotid gland tumor, cerebroma and renal cyst: A Chinese herb pharmaceutical composition for treating tumor is disclosed, wherein the composition is prepared by a predetermined amount of Common Selfheal, and a predetermined amount of Radixscrophulariae.... Agent: Anna Wu

20080274044 - Methods of administering liquid droplet aerosols of nanoparticulate drugs: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080274047 - Compositions and methods for treating proliferative disorders: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080274048 - Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.... Agent: Kramer Levin Naftalis & Frankel LLP

20080274049 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20080274046 - Radiolabelling: i

20080274051 - Diagnosis and treatment of mood disorders: The present invention relates to the diagnosis, treatment and monitoring of mood disorders. For example, a diagnosis may be performed by determining whether a monoamine oxidase in a vertebrate is elevated compared to a healthy control subject. Methods of monitoring treatments and methods for identifying treatments for mood disorders are... Agent: Suzannah K. Sundby Smith, Gambrell & Russel, LLP

20080274050 - Labelled adrenomedullin derivatives and their use for imaging and therapy: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging... Agent: Louis Tessier

20080274052 - Radioflorination methods: e

20080274053 - Tissue metabolic stress monitoring: Various pathophysiological states are determined by evaluating the rate of 17O-containing water production oxygen using proton MRI. The method can be used to identify viable but threatened myocardium, injured by viable muscle, penumbra tissue in a stroke patient, and the like.... Agent: Dickstein Shapiro LLP

20080274054 - Composite for thermo-sensitive cell-tissue transplanted scaffold and use thereof: A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. This invention also provides a method of treating... Agent: Wpat, PC Intellectual Property Attorneys

20080274055 - Framework residue substituted humanized col-1 antibodies and their use: The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding... Agent: Klarquist Sparkman, LLP

20080274056 - Nanoparticle delivery systems for membrane-integrating peptides: Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.... Agent: Washington University-mofo C/o Mofo S.d.

20080274057 - Staudinger reaction in imaging and therapy and kits for use in imaging and therapy: The Staudinger reaction can be used for activation of prodrugs or pro-imaging probes. The invention relates to a method of preparing and activating prodrugs or pro-imaging probes by using the Staudinger reaction and to kits for medical imaging and/or therapy comprising at least one prodrug and/or pro-imaging probe comprising at... Agent: Philips Intellectual Property & Standards

20080274058 - Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins: Benzofuran compounds which contain at least one detectable label selected from the group consisting of 131I, 123I, 124I, 125I, 76Br, 75Br, 18F, 19F, 11C, 13C, 14C and 3H are provided as amyloid imaging agents for detecting brain amyloid deposits as well as other amyloidogenic peptides associated with systemic or localized... Agent: Foley And Lardner LLP Suite 500

20080274059 - Mite fusion proteins: The present invention relates to fusion proteins comprising a Group I allergen and a Group II allergen from the genus Dermatophagoides, isolated nucleic acid coding for them and their use for the manufacture of a medicament to prevent or treat a mite allergic reaction.... Agent: Stites & Harbison PLLC

20080274060 - Therapeutic foam: A foam is described for injection treatment of varicose veins. The foam comprises a sclerosant liquid, e.g. polidocanol solution, and a gas. The gas comprises xenon, optionally together with at least one other physiologically acceptable gas which is readily absorbed in the body or blood of a patient. The gas... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080274061 - Method for treating a restless limb disorder: A method for treating a restless limb disorder such as restless legs syndrome in a subject comprises administering, transmucosally in the oronasopharyngeal chamber of the subject, one or more doses of rotigotine or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein each such dose comprises an amount effective to... Agent: Harness, Dickey, & Pierce, P.l.c

20080274062 - Glycyrrhizic acid compounds as a foamer in chemically-derived surfactant-free dentifrice: The present invention relates to dentifrices in general and dentifrices free of chemically-derived foaming agents in particular. Particularly, the present invention relates to an all-natural dentifrice (e.g., toothpaste) comprising a concentration of glycyrrhizic acid that is suitable to work as a foaming agent. Even more particularly, the present invention relates... Agent: Kevin M. Farrell Pierce Atwood

20080274063 - Supercritical co2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from: The present invention provides, in one aspect, to products made from a novel and non-obvious supercritical CO2 extract of the roots of Glycyrrhiza sp., effective as an anti-inflammatory, anti-bacterial, anti-fungal and anti-adherent agent, including, but not limited to, products for oral care and body care. The present invention also provides,... Agent: Kevin M. Farrell Pierce Atwood

20080274064 - Utilization of rhinologically active substances: Acyclic compounds containing an ethers functionality external to the ring can be used as rhinologically active substances. In the regions of the mouth, the throat and the airways they produce a refreshing and clearing feeling.... Agent: Akerman Senterfitt

20080274065 - Oral care regimen: The invention includes methods of cleaning an oral surface, maintaining oral health and/or increasing oral health. Such methods encompass contacting an oral surface with a primary oral care composition at least once daily, contacting the oral surface with a periodic oral care maintenance composition at least once monthly, wherein the... Agent: Colgate-palmolive Company

20080274066 - Compositions, methods, devices, and kits for maintaining or enhancing tooth whitening: Compositions, methods, devices, and kits for maintaining or enhancing tooth whitening in a subject are disclosed. The methods include applying a first tooth whitening composition to the teeth of the subject for a predetermined period of time and applying a second tooth whitening composition to the teeth of the subject... Agent: Discus Dental, LLC

20080274067 - Tooth whitening composition: An oral care composition comprising an active agent e.g. a whitening agent and a carrier including a carrier base comprising a wax and a substantivity agent. A method of whitening the teeth using the composition is also disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080274068 - External preparation for skin containing a phosphorlated saccharide: Provided is an external preparation for skin, comprising a phosphorylated saccharide. The phosphorylated saccharide may be an inorganic salt of a phosphorylated saccharide. The phosphorylated saccharide may be a calcium, magnesium, potassium, zinc, iron or sodium salt. Also provided is an external preparation for skin, comprising a phosphorylated saccharide and... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20080274071 - Powdery styling agents and the dispenser systems thereof: The present invention relates to agents for the setting and styling of keratin fibers, in particular human hair, from a suitable dispenser system in the form of a fine powder, which is optionally freshly ground, shaved or rasped only directly prior to use, and to the use of this preparation... Agent: Paul & Paul

20080274069 - Cosmetic preparations containing copolymers of ethyl methacrylate and at least one monoethylenically unsaturated carboxylic acid: Copolymers prepared by a process comprising free-radical polymerizing: (a) more than 15 to 40% by weight of at least one monoethylenically unsaturated carboxylic acid; (b) 30 to less than 85% by weight of ethyl methacrylate; and (c) 0 to 50% by weight of at least one additional free-radically polymerizable monomer... Agent: Connolly Bove Lodge & Hutz, LLP

20080274070 - Method for permanently reshaping keratin fibers comprising applying a poorly concentrated reducing compositions followed by drying: p

20080274072 - Insect repellants and insecticides: An insect repellant is in a sprayable gel formulation. The insect repellant is citronella based and may contain a deodorizer. An insecticide is in a sprayable gel formulation and may contain a deodorizer.... Agent: Michael S. Leonard Everest Intellectual Property Law Group

20080274073 - Process for producing aqueous emulsions and dispersions:

20080274074 - Method for controlled free radical polymerization or copolymerization of methacrylic and/or methacrylate monomers or exclusively methacrylic and/or methacrylate copolymers:

20080274075 - Poly(ethylene glycol) derivatives and process for their coupling to proteins: Novel compounds, including PEGylated proteins of the formula, methods for preparing such compounds, methods of using such compounds, and other compositions and methods, are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080274076 - Composition for use in controlling aedes aegypti mosquitoes: The present invention discloses a composition for use in luring Aedes aegypti mosquitoes to lay their eggs in a target site, which comprises of an effective amount n-heneicosane in a suitable organic solvent. The composition may also contain an effective amount of insecticide capable of killing the mosquito larvae soon... Agent: Ladas & Parry LLP

20080274079 - De novo synthesis of glucocorticoids in the epidermis and its uses and applications: The present invention relates to methods and compositions that control, i.e., antagonize/inhibit or agonize/stimulate, de novo glucocorticoid production in the skin. Such methods and compositions can be used for the prevention and/or treatment of a variety of skin conditions, including inflammation, acute wounds, chronic non-healing wounds, keloid, fibrotic or hypertrophic... Agent: Darby & Darby P.C.

20080274077 - Method for treating neurological disorders: The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination... Agent: David S Resnick Nixon Peabody

20080274078 - Novel uses: The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080274080 - Aza-peptide macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080274082 - Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080274084 - Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis: Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as Lactobacillus sp. and Saccharomyces sp., are disclosed for the treatment of chronic enterocolitis.... Agent: Knobbe Martens Olson & Bear LLP

20080274083 - Antiviral resistance mutants and applications thereof: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside... Agent: Knobbe Martens Olson & Bear LLP

20080274091 - Autologous t cell manufacturing processes: The invention provides novel processes for manufacturing autologous T cells, transducing T cells and expanding the transduced T cell population.... Agent: Virxsys C/o Mofo Sd

20080274092 - Erythrocytes containing arginine deiminase: Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. Said use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention... Agent: Stites & Harbison PLLC

20080274093 - Method of diminishing the symptoms of neurodegenerative disease: A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprises cells with induced antioxidant response element (ARE) mediated transcription,... Agent: Quarles & Brady LLP

20080274085 - Probiotic bifidobacterial species: A probiotic composition comprising a Bifidobacterium strain which has DNA sequence homology of greater than 40% to Bifidobacterium GC56, wherein Bifidobacterium GC56 was deposited at the Collection Nationale de Cultures de Micro-organismes (CNCM, Institut Pasteur) on 9 Dec. 2004 with accession number CNCM 1-3342.... Agent: Merchant & Gould PC

20080274087 - Brain tissue damage therapies: A cultured pluripotent animal cell that is CD13+, CD90+, and CD117−. Also disclosed are methods for making the cell and methods of treating a brain tissue damage and increasing the expression level of a neuraltrophic factor in a subject.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080274089 - Inflammation: This invention provides adult neural stem cell (aNSC) materials and methods for treating central nervous system disorders.... Agent: Marshall, Gerstein & Borun LLP

20080274088 - Mapc generation of lung tissue: The present invention relates to methods of improving function in lung tissue by administering a population of multipotent adult progenitor cells (“MAPCs”) or differentiated progeny thereof.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20080274090 - Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures: The subject invention concerns new methods which make it possible, for the first time, to grow functional islet-producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) in in vitro cultures. The subject invention also concerns the use of the in vitro grown IPSCs, IPCs and/or IdIs for... Agent: Beusse Wolter Sanks Mora & Maire

20080274086 - Use of cxcr4 protein expression on the surface of stem cells as a marker for tumor tropic potential: The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the... Agent: Davis Wright Tremaine LLP/los Angeles

20080274094 - Molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives thereof and related uses in medical field: The present invention relates to a molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives and related uses in medical field, for example for the treatment of the skin, mucosa and serosa, for the treatment of skin aging, cutaneous hyperpigmentation and skin diseases.... Agent: Casella & Hespos

20080274095 - Biocides: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).... Agent: Casimir Jones, S.c.

20080274097 - Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same: A booster comprising a plurality of microbubbles of a gas in a liquid, e.g. about 4×107 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth... Agent: Knobbe Martens Olson & Bear LLP

20080274096 - Fusion proteins having a modulated half-life in plasma: The present invention relates to fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein comprises a component that cleaves the amyloid beta (Ab) peptide e.g. neprilysin, insulin degrading enzyme (IDE), another component that modulates the half-life in plasma e.g. the Fc portion of IgG... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080274045 - Imaging, diagnosis and treatment of disease: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.... Agent: Wolf Greenfield & Sacks, P.C.

20080274081 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Bell, Boyd & Lloyd LLP

20080274100 - Antibodies and uses thereof: The present invention provides antibodies or fragments thereof that bind to co-receptor CCR5 or CXCR4.... Agent: Kenyon & Kenyon LLP

20080274099 - Antibodies of the ed-b domain of fibronectin, their construction and uses: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.... Agent: Millen, White, Zelano & Branigan, P.C.

20080274098 - Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject in need of such treatment an effective amount of a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080274101 - Stabilizing polypeptides which have been exposed to urea: Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20080274102 - Antibodies to nik, their preparation and use: An antibody or antibody fragment preparation being capable of specifically binding the amino acid sequence 60-76, 86-98, 135-149, 215-227, 363-377, 385-397, 405-419, 427-440, 509-522, 605-619, 635-649, 666-680, 696-711, 752-766, 836-851, 871-884, and/or 904-916 of NIK, or being capable of specifically binding a specific portion of the amino acid sequence is... Agent: Marshall, Gerstein & Borun LLP

20080274103 - Adenylyl cyclase antibodies, compositions and uses thereof: The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any... Agent: Klauber & Jackson

20080274106 - Mesothelioma therapeutic agent: The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R.... Agent: Foley And Lardner LLP Suite 500

20080274105 - Polypeptide variants with altered effector function: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.... Agent: Genentech, Inc.

20080274108 - Polypeptide variants with altered effector function: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.... Agent: Genentech, Inc.

20080274104 - Targeting a secreted pro-apoptotic factor for cancer therapeutics: The present invention concerns targeting a cell death factor associated with cancer. More specifically, an apoptosis-inducing factor is targeted to prevent destruction of non-cancerous cells. The factor may be a lipocalin molecule, and in specific embodiments its secretion and/or the secreted form is targeted by an inhibitory agent, such as... Agent: Fulbright & Jaworski, LLP

20080274107 - Tyrosine kinase inhibitors: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like... Agent: Merck And Co., Inc

20080274109 - Myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4): There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine β8 (CKβ8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-γ and chemokine β1 (CKβ1 or ckb-1)), and a macrophage inhibitory... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080274110 - Cell death-inducing agents: To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was... Agent: Fish & Richardson PC

20080274111 - Pancreatic cancer genes: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20080274114 - Anti-egfr antibodies: The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.... Agent: Eli Lilly & Company

20080274113 - Method and compositions for prevention and treatment of malaria infections: Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided. In addition methods for identifying agents which inhibit the function of... Agent: Licata & Tyrrell P.C.

20080274112 - Nogo receptor antagonists: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080274115 - Soluble erbb3 methods of detection and antibodies: Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or... Agent: Cohen & Grigsby, P.C.

20080274116 - Lipids, lipid complexes and use thereof: The present invention is related to a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080274117 - Validation of tssk family members and tsks as male contraceptive targets: The present invention relates to a family of testis specific kinases (the TSSK family) and a substrate (TSKS) of TSSK, nucleic acid sequences encoding those kinases and substrate, and antibodies and antagonists against the kinases and substrate, methods of regulating these proteins, and their use as contraceptive targets.... Agent: University Of Virginia Patent Foundation

20080274118 - Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one... Agent: Alston & Bird LLP

20080274120 - Histone deacetylase (hdac) inhibitors (pxd101) for the treatment of cancer alone or in combination with chemotherapeutic agent: The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a... Agent: Michael Best & Friedrich LLP

20080274119 - Use of opioid antagonists to attenuate endothelial cell proliferation and migration: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.... Agent: Michael Best & Friedrich LLP

20080274121 - Inhibition of angiogenesis by mithramycin: We disclose a method of inhibiting angiogenesis in a mammal by administering by a subcutaneous or intraperitoneal route to a tissue in the mammal where angiogenesis is occurring a composition comprising mithramycin and a pharmaceutically-acceptable carrier. We have found a subcutaneous or intraperitoneal dose from about 10 μg mithramycin per... Agent: Williams, Morgan & Amerson

20080274124 - Ligand for g-protein coupled receptor gpr72 and uses thereof: The present invention relates to methods, reagents and kits for detecting of GPR72 polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against GPR72. It further relates to substances for preventing, treating and/or alleviating diseases or disorders characterized by dysregulation of... Agent: Edwards Angell Palmer & Dodge LLP

20080274122 - Plks as modifiers of the beta catenin pathway and methods of use: Human PLK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PLK are provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080274123 - Specific binding members against synaptophysin: The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and... Agent: Michael Best & Friedrich LLP

20080274127 - Amino acid supplementation for a healthy microbiota ecosystem: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of... Agent: Bell, Boyd & Lloyd LLP

20080274125 - Human stem cell lines derived from es cells and uses for production of vaccines and recombinant proteins: The present invention concerns the field of biology and virology. In particular, the invention concerns a method for obtaining human cell lines, in particular human stem cells derived from human embryonic stem cells, the method comprising separation from the serum, the feeder layer and at least one growth factor. The... Agent: Buchanan, Ingersoll & Rooney PC

20080274126 - Oral vaccines for fish: The invention relates to the development, composition and production of mucosal (oral) vaccines for fish. More specifically, the invention relates to protein complexes for the delivery of antigens to and across mucosal surfaces of fish for the induction of an immune response, and to the production of said complexes in... Agent: Hoffmann & Baron, LLP

20080274128 - Heat shock protein-based vaccines and immunotherapies: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment... Agent: Jones Day

20080274129 - Hla-a2 tumor associated antigen peptides and compositions: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080274130 - Rabies virus vector systems and compositions and methods thereof: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the... Agent: Klarquist Sparkman, LLP

20080274131 - Molecular antigen arrary: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080274132 - Vaccines for blocking transmission of plasmodium vivax: The present invention relates novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28... Agent: Townsend And Townsend And Crew, LLP

20080274133 - Soluble bifunctional proteins: The present invention provides a soluble bifunctional protein comprising an association between a T cell receptor and a superantigen. Also provided are therapeutic compositions comprising said bifunctional proteins and methods for the use thereof.... Agent: Banner & Witcoff, Ltd.

20080274134 - Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex: This invention provides methods for eliciting an immune response in a subject comprising administering to the subject as part of a regimen (i) more than one dose of a nucleic acid prime, and (ii) more than one dose of a protein boost composition, wherein each dose of the nucleic acid... Agent: Cooper & Dunham, LLP

20080274135 - Measuring degree of polymerisation for meningococcal capsular saccharides that contain sialic acid: The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal... Agent: Novartis Vaccines And Diagnostics Inc.

20080274136 - Polyvalent attenuated live vaccine for preventing and curing vibriosis of cultivated fish: A novel polyvalent attenuated live bacterial vaccine for preventing and curing vibriosis of cultivated fish is provided. The vaccine mainly comprises attenuated deletion strain of Vibrio anguillarum without marker gene, which has significant low toxicity, but remains immunogenicity against wild type strain of V. anguillarum, as compared with wild type... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080274137 - Dna plasmids having improved expression and stability: The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest. More particularly, the present invention provides for DNA plasmids with increased expression and stability in compositions and methods useful for DNA vaccines.... Agent: Judy Jarecki-black, Ph.d.,j.d

20080274138 - Formulation of sugar solutions for continuous ultracentrifugation for virus purification: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher... Agent: King & Spalding

20080274139 - Attenuated microorganisms for the treatment of infection: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080274140 - Vaccines and methods for using the same: Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes an protein selected from the group consisting of: CTACK, TECK, MEC and... Agent: Pepper Hamilton LLP

20080274141 - Animal cells and processes for the replication of influenza viruses: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the... Agent: Novartis Vaccines And Diagnostics Inc.

20080274142 - Chimeric flaviviruses: The invention provides flavivirus vaccines and methods of making and using these vaccines.... Agent: Clark & Elbing LLP

20080274143 - Chloroplasts engineering to express pharmaceutical proteins: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts,... Agent: Timothy H. Van Dyke

20080274144 - Hcv e1 comprising specific disulfide bridges: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins... Agent: Nixon & Vanderhye, PC

20080274145 - Deacylation of lps in gram negative bacteria: The current invention provides new Gram negative polypeptides exhibiting lipid A 3-O-deacylase activity and are capable of modifying and/or detoxifying gram negative LPS. The present invention also provides Gram negative bacteria, Gram negative bacterial lipopolysaccharides (LPS) and compositions comprising LPS, which are provided with or treated with a 3-O-deacylase activity... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080274146 - Application system for a plaster containing an active ingredient and a controlled-release agent for said active ingredient: The present invention relates to an application system for an active ingredient release system, comprising a film-form application strip, which is in each case bonded detachably to an active ingredient-containing plaster and a separate active ingredient release regulator separate there from.... Agent: Crowell & Moring LLP Intellectual Property Group

20080274151 - Cosmetic composition: A cosmetic composition comprising a cosmetic base selected from the group consisting of liquid base, paste base and powder base, a perfume ingredient, and polyamide particles wherein the polyamide particles comprise at least either of the porous polyamide particles of the following (1) and (2) shows satisfactory shape retention on... Agent: Nixon Peabody, LLP

20080274152 - Cosmetic powder compositions having large particle size color travel effect pigments: A cosmetic composition preferably in powder form comprising pigments having a color travel effect, wherein said composition contains a sufficient amount of large particle size color travel pigments having a D50 particle size of at least 40 μm up to about 150 μm to retain the color travel effect upon... Agent: Millen, White, Zelano & Branigan, P.C.

20080274147 - Dry limited use cloth: The present invention is directed to a dry cleansing cloth that comprises at least one personal care composition imparted to the cloth, wherein the composition acts as a visual indicator of the compositions depletion with each use, eventually signaling the consumer for the need of a replacement cloth. Accordingly, the... Agent: Valerie Calloway Chief Intellectual Property Counsel

20080274149 - Encapsulation and controlled release of biologically active ingredients with enzymatically degradable microparticulate, hyperbranched polymers: The invention provides encapsulated, microparticulate active ingredient formulations for the controlled release of active ingredients on skin and skin appendages consisting of encapsulation material as casing and at least one enclosed biologically active ingredient as core, which is characterized in that enzymatically degradable organic hyperbranched polymers containing ester groups are... Agent: Scully Scott Murphy & Presser, PC

20080274148 - Microcapsule composition: The present invention comprises an oral care composition comprising a microcapsule containing a coated water soluble dye particle that is incorporated into a liquid hydrophobic material. Suitably the microcapsule containing the water soluble dye forms part of a clear gel toothpaste formulation.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080274150 - Process for removing odors from hydrocarbons: A process for removing odors from hydrocarbons is disclosed. Odor-free hydrocarbons obtained by the process are described, which hydrocarbons are particularly suitable for use in cosmetic applications. Cosmetic formulations which contain the odor-free hydrocarbons are also described.... Agent: Fox Rothschild LLP

20080274153 - Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations: An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky

20080274154 - Water-based, antimicrobially active, dispersion concentrates: Highly concentrated, water-based dispersions of certain lipophilic and/or hydrophobic antimicrobially active materials are stabilized to a surprising degree by a surfactant combination including a nonionic acrylic graft copolymer surfactant and a alkoxylated polyarylphenol phosphate ester surfactant. The active materials may be present in dispersion concentrates of the present invention singly... Agent: Troy Corporation

20080274155 - Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them: The invention provides chimeric cannulae polypeptides and nanotubules and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one... Agent: Verenium C/o Mofo S.d.

20080274157 - Cartilage implant plug with fibrin glue and method for implantation: The invention is directed toward a cartilage repair assembly comprising a shaped structure of subchondral bone with an integral overlying cartilage cap which is treated to remove cellular debris and proteoglycans and milled cartilage in a bioabsorbable carrier. The shaped structure is dimensioned to fit in a drilled bore in... Agent: Greenberg Traurig, LLP

20080274156 - Composition forstimulating bone growth and differentiation and method for isolating same: This invention relates to isolated heparan sulphate and use thereof to stimulate bone cell growth and differentiation. The invention also relates to use of heparan sulphate with implants, prosthesis and bioscaffolds to repair and regenerate bone. Such use may be for repair of damaged tissue including bone tissue, for example... Agent: Stout, Uxa, Buyan & Mullins LLP

20080274159 - Drug formulations for coating medical devices: The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an... Agent: Knobbe Martens Olson & Bear LLP

20080274158 - Hydrazide compounds with angiogenic activity: wherein P is a water-soluble, biodegradable polymer, R1 is hydrogen, lower alkyl, lower alkoxy or —R2—C(═O)—NH—NH—R3; each R2 is independently —CH2—, —NH— or O; and each R3 is independently hydrogen or a residue of a naturally occurring alpha-L-amino acid or dipeptide thereof. Polymer networks crosslinked with hydrazide compounds are also... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080274160 - Implant material: An implant material includes a base material that includes, as a main component, a partially stabilized zirconia having an average crystal particle diameter of 0.3 μm or less and a porous covering layer that includes ceramic as a main component and has a center pore diameter within a range of... Agent: Kinney & Lange, P.A.

20080274161 - Hydrogels and hydrogel particles: The invention provides fabricated hydrogels, hydrogel particles, hydrogel containing compositions, and methods of making the same. The invention also provides methods of implanting, injecting, or administering the hydrogels, hydrogel particles, or the hydrogel containing compositions to treat a subject in need. Methods of crosslinking pre-solidified or pre-gelled hydrogel particles and... Agent: Proskauer Rose LLP

20080274162 - Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository: This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses... Agent: Jeffrey And Beth Nessa

20080274163 - Nose and throat anti-influenza solution and method of use: A nose and throat anti-influenza solution is described that decreases the likelihood influenza infection and its spread. The solution's components are readily available and have been used to treat humans for other ailments previously, leading to an easily implemented, scalable, safe, and cost-effective solution. The core components of the solution... Agent: Triangle Patents, P.l.l.c.

20080274164 - Atrium patch: The invention relates to a plaster composition for administering active agents in and to bodily orifices, such as e.g. the buccal cavity, lips or genitalia.... Agent: Friedrich Kueffner

20080274165 - Wound healing compositions containing keratin biomaterials: Disclosed are keratin preparations for use in medical applications. Methods of treating wounds are provided, wherein keratin preparations are applied to the wound in a treatment effective amount. Methods of treating burn wounds are also provided. Surgical or paramedic aids are provided, comprising a substrate with keratin preparations provided thereon.... Agent: Myers Bigel Sibley & Sajovec

20080274166 - Patch for transdermal drug delivery: Apparatus is provided including a transdermal drug delivery patch product (10, 100), which includes a patch (20, 120), which includes a drug; and protective packaging, adapted to store the patch (20, 120), and to allow the drug to dry while the patch (20, 120) is stored in the protective packaging.... Agent: Darby & Darby P.C.

20080274168 - Transdermal delivery device disposal system: The present invention relates to a transdermal delivery device disposal system for disposing of a transdermal delivery device containing at least one pharmaceutically active component. The disposal system contains at least one sheet or substrate on which an adhesive is coated; and one or more of the following components: (a)... Agent: Duane Morris LLP

20080274167 - Transdermal therapeutic system (tts) with fentanyl as active ingredient: The invention relates to transdermal therapeutic systems with fentanyl or an analogous fentanyl derivative as active ingredient. In order to prevent inadvertent overdosage by uncontrolled release of active ingredient as a result of damage, the active ingredient is contained in fluid-filled micro-reservoirs in the layer containing the active ingredient. The... Agent: Frommer Lawrence & Haug

20080274173 - Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.... Agent: Choate, Hall & Stewart LLP

20080274172 - Liposome preparation method: The invention relates to a method for preparing liposomes with at least two uniformly distributed phospholipids without using organic solvents.... Agent: Sheridan Ross PC

20080274170 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20080274169 - Photosensitizer formulations for topical applications: Highly flexible penetrating liposomal carrier systems are formulated with enhanced skin penetration properties. These specialized formulations of highly flexible penetrating liposomal delivery systems comprise one or more phospholipids, lysophosphatides and hydrophobic photosensitizer. This new formulations can squeeze liposomal particles through intercellular regions of stratum corneum as intact structures, and, in... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20080274171 - Renin inhibitors nitroderivatives: having wider pharmacological activity and enhanced tolerability. They can be employed for treating or preventing congestive heart failure, coronary diseases, cardiac insufficiency, left ventricular dysfunction and hypertrophy, cardiac fibrosis, myocardial ischemia, stroke, atherosclerosis, restenosis post angioplasty, renal insufficiency, renal ischemia, renal failure, renal fibrosis, glomerulonephritis, renal colic, ocular and pulmonary... Agent: Arent Fox LLP

20080274174 - Stable pancreatic enzyme compositions: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080274175 - Compositions comprising edible oils and vitamins and/or minerals and methods for making the compositions: The invention provides compositions for an administration to a mammal orally or in a suppository that include one or more edible oils (preferably including one or more omega-3 fatty acids), one or more plant stanols, phytosterols, or esters thereof, and admixed in the one or more edible oils one or... Agent: Keith D Parr Roberta L Hastreiter

20080274177 - Controlled release dosage forms: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080274176 - Pharmaceutical lipid compositions: The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile,... Agent: Nixon Peabody

20080274178 - Orally disintegrating tablet: By mixing an active ingredient, crystalline cellulose, an inorganic excipient, carmellose, and a lubricant at not more than 0.8% by weight per tablet, and compressing the mixture, or compressing the mixture by an external lubricating method, a palatable orally disintegrating tablet which maintains a tablet hardness and exhibits good disintegrating... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080274180 - Extended release pharmaceutical composition of metformin and a process for producing it: A pharmaceutical composition in the form of tablets constitutes an orally administered, controlled drug delivery system that will provide increased retention time of the device in the stomach over conventional dosage forms and release metformin or its pharmaceutically acceptable salt in a controllable manner, and further that is easy and... Agent: Merchant & Gould PC

20080274179 - Supercritical co2 liquorice extract and products made there from: The present invention provides, in one aspect, to products made from a novel and non-obvious supercritical CO2 extract of the roots of Glycyrrhiza sp., effective as an anti-inflammatory, anti-bacterial, anti-fungal and anti-adherent agent, including, but not limited to, products for oral care and body care.... Agent: Kevin M. Farrell Pierce Atwood

20080274181 - Bupropion hydrobromide and therapeutic applications: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080274182 - Tablet coatings made from modified carboxymethylcellulose materials: Coated tablets for the delivery of active ingredients to a user are provided. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production... Agent: J.m. Huber Corporation Legal Department

20080274184 - Ecm-based graft material: This invention is directed to graft materials comprising an extracellular matrix (ECM) and therapeutic agents. This invention is also directed to methods of using the graft materials for healing of damaged or diseased tissues on a patient's body.... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20080274187 - Hard capsule composition and method of use: A hard shell capsule composition and method which is gelatin, BSE, plasticizer and preservative free, which is less sensitive to temperature, humidity and climate changes during manufacture and storage while remaining dimensionally and microbially stable.... Agent: Karl Wei Cao

20080274186 - Nell-1 enhanced bone mineralization: Provided herein are methods for enhancing bone mineralization for bone repair or regeneration and compositions and grafts therefor. Methods for screening agents that enhance or modulate NELL-1 gene expression or NELL-1 protein production in a cell are also provided.... Agent: Squire, Sanders & Dempsey L.L.P.

20080274188 - Oral vehicle for systemic pharmaceuticals: Systemic drug delivery includes boluses of a semi-solid agar gel, each containing active ingredients, packed singly or in co-operating sets in blister packs, or loose in a container. When placed in the mouth the bolus is disrupted, comes apart, and releases the active ingredients. Sialogogues, flavours, and other additives assist... Agent: Young & Thompson

20080274189 - Organic compounds comprising a glycopyrr onium salt: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.... Agent: Novartis Corporate Intellectual Property

20080274185 - Shape and dimension maintenance of soft tissue grafts by stem cells: Methods and compositions for de novo and in vivo synthesis of soft tissue in predefined shape and dimensions from adult mesenchymal stem cells (MSCs) within a biocompatible scaffold are described. Scaffolds are implanted in vivo in a host animal and fabricated therein, or maintained ex vivo. Inducing angiogenesis enhances success... Agent: Sonnenschein Nath & Rosenthal LLP

20080274183 - Thermoplastic articles containing a medicament: A composition suitable for making a fiber or a film includes a biocompatible primary polymer matrix which forms a continuous phase of the composition and an active agent forming a substantially discontinuous phase of the composition. The biocompatible primary polymeric matrix has a glass transition temperature of less than about... Agent: Eastman Chemical Company

20080274190 - Temperature and ph - sensitive block copolymer having excellent gel strength, method of preparing the same, and drug delivery system using the same: Disclosed herein is a temperature- and pH-sensitive block copolymer having excellent gel strength, including: (a) a poly(ethylene glycol)-based compound (A) or a copolymer (B) of the poly(ethylene glycol)-based compound (A) and a biodegradable polymer; and (b) a polyurethane-based oligomer (C). Further, a method of preparing a temperature and pH-sensitive block... Agent: Rabin & Berdo, PC

20080274191 - Bioadhesive composition with programmed release: The invention relates to novel viscous liquid compositions for producing pasty forms having a prolonged action and/or release for local applications. These compositions are characterized in that the long-lasting action and/or the prolonged release of the active substance is obtained by the in-situ formation of a matrix film having an... Agent: Jerome D. Jackson (jackson Patent Law Office)

20080274192 - Pharmaceutical compositions comprising an amorphous form of a vegf-r-inhibitor: A pharmaceutical composition comprising the compound 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or a pharmaceutically acceptable salt or solvate thereof, in an amorphous form.... Agent: Pfizer Inc

20080274195 - Compositions and methods for making and using nanoemulsions: The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased Tmax, increased Cmax, and increased AUC.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080274199 - Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed... Agent: Foley And Lardner LLP Suite 500

20080274197 - Lyophilized formulation: For clinical application of cis[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(R1)]platinum(II) (R1 is an alkanoyloxy group having 6 to 20 carbon atoms), the present invention aims at providing a formulation which prevents layer separation and changes in viscosity, shows fine suspendability, and which is easy to handle during administration. The formulation of the present invention is... Agent: Birch Stewart Kolasch & Birch

20080274196 - Oral pharmaceutical suspension compositions of fexofenadine: An oral, pharmaceutical suspension composition of Fexofenadine. Fexofenadine is a mixture of compacted Fexofenadine and plain fexofenadine in a ratio of 0.01:0.99 to 0.99 to 0.01 having a mean particle size of fexofenadine particles in the range of 10μ and 250 μ.An oral, pharmaceutical suspension composition of Fexofenadine, which is... Agent: Merchant & Gould PC

20080274193 - Retinoic acid-containing antidiabetic agent: The present invention aims to provide a novel agent for treating and/or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of β cells and a patient with type II diabetes suffering from dysfunction... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080274194 - Stabilized hme composition with small drug particles: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing... Agent: Chalker Flores, LLP

20080274198 - Use of multilayered pigments in the food and pharmaceuticals sector: The present invention relates to the use of multilayered pigments based on platelet-shaped substrates for colouring food and pharmaceutical products.... Agent: Millen, White, Zelano & Branigan, P.C.

20080274200 - Dose titratable liquid dosage forms of acid labile drugs: Provided herein are pharmaceutical formulations comprising micro-granules and a liquid suspension vehicle having a pH less than 6.0 and a viscosity sufficient to suspend the micro-granules. The micro-granules typically contain a PPI which therefore makes the above formulation, as well as kits for making the above formulation, useful for alleviating... Agent: Dykema Gossett PLLC

20080274201 - Gels for encapsulation of biological materials: This invention provides novel methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a “glue” to cause more than one biological substance to adhere together, or as... Agent: Knobbe Martens Olson & Bear LLP

20080274202 - Compositions and method for brain specific targeted delivery of therapeutic agents: Disclosed are methods and compositions for delivering a therapeutic agent to target organs or tissues, such as brain. The methods and compositions use bone marrow stem cells, monocytes, macrophages or microglial cells to deliver the therapeutic agent associated with nanoparticles to the target organ or tissue.... Agent: Michael Best & Friedrich LLP

20080274203 - Bioeffective krill oil compositions: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2... Agent: Casimir Jones, S.c.

20080274204 - Ultra fine dead sea mineral compound and method of manufacture: An ultra fine mineral compound and method of processing native Dead Sea minerals into this ultra fine mineral compound that can be used to manufacture all natural Dead Sea mineral compositions particularly compositions for use in bath and body products is disclosed. Even with the extreme ionic character of the... Agent: Jackson Walker, L.L.P.

20080274205 - Ena mineral bioactive solution, manufacturing method thereof and its application for the osteoporosis prevention: The present invention is related to a method of manufacture of an alkaline mineral bioactive solution of which raw materials are squid bones burnt at a high temperature and crushed powder of red seaweeds and to compositions and health foods having the efficacy for the prevention of osteoporosis. The alkaline... Agent: Ipla P.A.

20080274206 - Stabilised oxygen releasing composition: The present invention relates to stabilised liquid oxygen releasing composition comprising a component (a) selected from the salts consisting of cations An+ and anions derived from halogen oxides according to the general formula [OmX]− wherein A is a metal selected from Groups 1 or 2 of the Periodic System of... Agent: Foley And Lardner LLP Suite 500

20080274207 - Antimicrobial lenses, processes to prepare them and methods of their use: This invention relates to solutions for packaging ophthalmic devices comprising at least one antimicrobial metal salt which prevent the loss of said antimicrobial metal salt during autoclaving and storage.... Agent: Philip S. Johnson Johnson & Johnson

20080274208 - Water treatment containing dbnpa for use in sanitizing recreational water: The present invention is directed to a composition for reducing the levels of microorganisms in recreational water systems, comprising: (1) a biocidal effective amount of dibromonitrilopropionamide (DBNPA); (2) optionally, a biocidal effective amount of an algaecide selected from the group consisting of didecyldimethylammonium chloride (DDAC), zinc, and copper; and (3)... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080274209 - Methods of treating inflammation: Disclosed are compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating inflammatory symptoms and lesionous symptoms of a viral infection involving applying an effective amount of the pharmaceutical composition to the inflammation... Agent: Amin, Turocy & Calvin, LLP

20080274210 - Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification... Agent: Albert Wai-kit Chan Law Offices Of Albert Wai-kit Chan, LLC

20080274211 - Methods and compositions for controlling micororganism populations in the digestive system of animals: The invention is related to methods and compositions for controlling microorganism populations in the digestive system of an animal. In an embodiment, the invention is a composition for reducing the bacterial load in the digestive tract of an animal including a saponin containing composition and an anti-microbial agent. Other embodiments... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20080274213 - Drug for ameliorating male climacteric disorders: It is intended to provide a highly safe pharmaceutical drug or food that inhibits reduction in blood testosterone level and prevents or ameliorates symptoms and so on associated with male climacteric disorders. The present invention provides a drug for inhibiting reduction in blood testosterone level and a drug for ameliorating... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080274212 - Herbal extract for renal disorders: The present invention further relates to a method of treatment of renal disorders such as recurrent urinary tract infection particularly occurring due to relapsing E. coli, Klebsiella and other gram negative infections and to a method of treatment of nephrotic syndrome using standardized extract of Tinospora cordifolia as an immunoadjuvant... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080274214 - Medicament for the prevention and treatment of influenza: The invention relates to the use of an extract from plants of the genus Cistus for the preparation of a medicament for the prevention and treatment of influenza, in particular of the avian flu and viral strains derived from the avian flu in the course of an impending pandemic.... Agent: Kilyk & Bowersox, P.l.l.c.

20080274215 - Composition for treatment of cold and flu: The present invention is a composition delivering therapeutically effective amounts of Andrographis Paniculata standardized to 5.6% of Andrographolide:Siberian Ginseng:American Ginseng:Vitamin C in a single dosage unit.... Agent: Robert M. Schwartz, P.A.

20080274216 - Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus: A medicinal preparation, a process, a nutritional composition and regenerative and insulin potentiating method for humans and also for mammals for prevention, treatment and management/glycemic control of diabetes mellitus by obtaining optimum glucose level in blood, by administering an extract of Costus pictus to produce above effect in a dose... Agent: Jyoti C. Iyer, Esq.

20080274217 - Oral compositions and route of administration for the delivery of a thylakoid extract: The present invention provides a new use for a thylakoid extract, that is for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, for... Agent: Marshall, Gerstein & Borun LLP

20080274218 - Gnetum extract: A Gnetum extract having antibacterial activity and antioxidant activity (radical scavenging activity), obtained from Gnetum fruit or Gnetum seed without the need to conduct any special operation. This Gnetum extract exerts various physiological (pharmacological) activities and hence can be used as an active ingredient of food, aliment (nutritional supplement), medicine,... Agent: Kratz, Quintos & Hanson, LLP